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The tumour microenvironment
Cancer is an important disease in dogs, and is twice as frequent (McEwen, 1989) 
and progresses more rapidly than in man (Glickman and Domanski, 1986). To 
understand the kinetics of tumour growth, it is necessary to learn about the tumour 
cell microenvironment. There is a large amount of information on the role of tumour 
microenvironment on the development and progression of human cancer. However, 
there is little research done on the role of stroma and extracellular matrix components 
(ECM) in the development and progression of canine cancer. A better understanding 
of the tumour environment will likely increase our awareness of the importance of the 
combinatorial signals that support and promote tumour cell growth, and invasion and 
metastasis, and eventually result in the identification of new therapeutics targeting the 
stroma and ECM.
   Tumour invasion and metastasis result from aberrant communication 
between tumour cells and microenvironment. The microenvironment consists of a 
variety of host cells: vascular cells (lympho-endothelial cells, vascular endothelial cells 
and pericytes, fibroblasts, myofibroblasts and inflammatory cells, and this constitutes 
about half of the tumour mass (Iozzo, 1988). Host stromal cells, in collaboration with 
tumour cells produce the ECM molecules, proteinases and cytokines. Interaction between 
host cells, tumour cells and ECM molecules can have restrictive or permissive influence 
on the behaviour of tumour cells. During the growth and invasion, or establishment of 
metastatic foci, there is a continuous remodelling of the stroma and ECM components 
by various degrees of biosynthesis and degradation (Iozzo, 1984; Liotta et al., 1983). 
Remodelling of tumour environment takes place through three interrelated mechanisms: 
(a) abnormal degradation of ECM components; (b) direct production of ECM by tumour 
cells, or tumour-cell induction of ECM components production by stromal cells; and (c) 
tumour-cell induction of stromal cell phenotypic differentiation. 
  Tumour cells activate stroma through production and secretion of 
stimulatory growth factors (Brown et al., 1999). The locally activated microenvironment 
in turn modifies progression of the tumour cells. The functional association of cancer 
cells with their surrounding tissues forms a new ‘tissue’ that changes as malignancy 
progresses and it is responsive and supportive to tumours. Investigation of this process 
might provide new insights into the mechanisms of tumourigenesis and could also lead 
to new therapeutic targets. 
In the following parts of this review, stromal cell and ECM changes occurring during 
tumourigenesis will be discussed.
Stromal cell changes in tumours 
Fibroblasts constitute a major stromal compartment of many tumours (Sappino et al., 
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1990). In many solid tumours, there is proliferation of fibroblasts around tumour cells, 
and there is novel expression of α-smooth muscle actin by these cells. This reaction 
of stromal cells to tumour cells was termed desmoplasia (Sappino et al., 1990). The 
fibroblasts that comprise the tumour stroma have been termed peritumoral fibroblasts, 
reactive stroma, carcinoma-associated fibroblasts, and myofibroblasts. For the purpose 
of this thesis we refer to them as myofibroblasts. 
  Myofibroblasts were first described by Gabbiani and co-workers 
as smooth muscle-like fibroblasts (Gabbiani et al., 1971). Morphologically, 
myofibroblasts are defined by contractile bundles of microfilaments, well-developed 
cell-matrix interactions and intercellular gap junctions (de Wever and Mareel, 2002). 
Immunologically, myofibroblasts are defined by positive expression of smooth muscle 
cell markers such as α-smooth muscle actin, smooth muscle myosin, caplonin, and α –1 
integrin (Rønnov-Jessen et al., 1995). 
Origin of myofibroblasts in tumours 
Despite the wide occurrence of myofibroblasts, and numerous in vitro and in vivo studies 
detailing their morphological, immunohistochemical, biochemical andpharmacological 
characterisation, their origin is still not clear. Theoretically myofibroblasts can 
originate from stromal fibroblasts, smooth muscle cells or pericytes. Analysis of 
human breast tumours revealed that most of the myofibroblasts originated from pre-
existing fibroblasts with a small percentage originating from smooth muscle cells and 
pericytes (Rønnov-Jessen et al., 1995). Myofibroblasts lack desmin and prekeratin and 
contain only one type of intermediate filament, vimentin, suggesting that these cells 
may be more closely related to fibroblasts than smooth muscle cells.    
  The inductive mechanisms involved in the phenotypic transformation 
of fibroblasts to myofibroblasts in tumours are poorly understood, but is thought to be 
modulated by mechanical stress and cytokines, among which is transforming growth 
factor (TGF-β).  In vitro experiments have shown that several tumour cell lines induce 
transformation of stromal fibroblasts from different tissues to myofibroblasts (Peehl and 
Sellers, 1998; Valenti, et al., 2001) and, this is mediated by TGF-β (Rønnov Jessen et al., 
1993; Lijnen et al., 2003). Tumour infiltrative lymphocytes (especially CD8+ cytotoxic/
suppressor T-cells) also produce TGF- β (Merogi et al., 1997; Liyanage et al., 2002). 
TGF- β occupies a central position in the signalling network that controls growth, 
differentiation, ECM components deposition, changes in cellular adhesive properties 
and tumour progression (Ignotz and Massagué, 1986 & 1987; Wiseman et al., 1988, 
Locci et al., 1993; Massagué et al., 2000). Other cytokines including platelet derived 
growth factor (PDGF) and granulocyte macrophage-colon stimulating factor (GM-
CSF) have an indirect effect on myofibroblastic differentiation. PDGF is a mitogen and 
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chemoattractant for mesenchymal cells. It is responsible for enhanced proliferation of 
myofibroblasts and also recruits macrophages that produce TGF- β (Rønnov-Jessen and 
Petersen, 1993). GM-CSF indirectly induces myofibroblast transformation by recruiting 
macrophages, which produce TGF- β (Xing et al., 1997). 
Functions of myofibroblasts in tumours
 During tumour progression, both the percentage of myofibroblasts 
and their localization change (De Wever and Mareel, 2002). For example, in canine 
gastrointestinal carcinomas, myofibroblasts are found in higher proportions than in 
adenomas (Mukaratirwa et al., 2003), and in canine transmissible venereal tumours, 
myofibroblasts are found in higher proportions in regressing tumours than in progressing 
tumours (Chapter 7). As the predominant cell type in tumour stroma, the myofibroblast 
is responsible for the production and secretion of most of the ECM components, such as 
collagen I, collagen II, fibronectin, tenascin and versican (Lagace et al., 1985; Mackie 
et al., 1987; Hauptmann et al., 1995; Hanamura et al., 1997), and proteolytic enzymes 
and their inhibitors (Nielsen et al., 1996; DeClerck et al., 2000). Production of these 
components results in ECM remodelling that could stimulate tumour cell growth and 
invasion. In addition, myofibroblasts have been reported to secrete growth factors that 
promote angiogenesis (Sato et al., 1993; Shimo et al., 1999). Paracrine growth factors 
secreted by myofibroblasts include insulin-like growth factors, plasminogen related 
growth factors and epidermal growth factors. These growth factors are mitogens for 
several epithelial cell lines and induce tumour cell proliferation. In addition to cell 
proliferation, myofibroblasts have been shown to induce differentiation of several 
epithelial tumour cell lines (Montessano et al., 1991; Brinkmann et al., 1995).  In vitro 
studies have shown that myofibroblasts prevent penetration of T-lymphocytes and 
macrophages within tumour nodules, thus preventing physical contact with cancer cells 
(Lieubeau et al., 1999).
Altered extracellular matrix protein expression in tumours   
   The extracellular matrix is a complex structural entity 
surrounding and supporting cells that are found within normal and pathologic tissues, 
including neoplastic tissue. This matrix provides the structural and biomechanical 
properties which are crucial for connective tissue functions. In all tissues and neoplastic 
conditions, the cells interact   with ECM components through specific receptors, e.g. 
integrins. Signals transmitted via these receptors control many aspects of cellular 
life, for instance proliferation, differentiation, maintenance of differentiation state 
and survival. The ECM, which is produced by collaboration between stromal cell and 
tumour cells, provides structural scaffolding for cells, as well as contextual information. 
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In tumours, the ECM is continously modified by the tumour cells and adapted to the 
needs of the tumour cells, favouring tumour progression. This is achieved by controlled 
enzymatic degradation and changes in the components secreted by the tumour and 
stromal cells. The balance between degradation and synthesis of ECM components is 
disturbed resulting in altered expression of some ECM components. This generates a 
”tumour extracellular matrix” which differs from that of normal tissues. The ECM is 
composed of 3 major classes of biomolecules: structural proteins, glycoproteins, and 
proteoglycans.          
  Collagen is the major structural protein comprising the ECM. There are 
at least 12 types of collagen. Types I, II and III are the most abundant and form fibrils 
of similar structure. Type IV collagen forms a two-dimensional reticulum and is a major 
component of the basal lamina. Collagens are predominantly synthesized by fibroblasts, 
but epithelial cells also synthesize these proteins. Altered expression of collagen has 
been reported in several tumours (Giannelli et al., 2001; Parikka et al., 2001 & 2003; 
Han et al., 2003).                                                                   
  A glycoprotein is a macromolecule composed of protein and 
carbohydrate. The carbohydrate is usually attached to the protein in a postranslational 
modification, at either asparagine, hydroxylysine, serine or theonine. Fibronectin and 
tenascin are the most important glycoproteins which have altered expression in tumours. 
The role of fibronectins is to attach cells to a variety of extracellular matrices. At least 20 
different fibronectin chains have been identified that arise by alternative RNA splicing 
of the primary transcript from a single fibronectin gene. Tenascin-C was initially 
independently isolated from different species, and was given the several names including 
cytotactin (Grumet et al.,) myotendinous antigen (Chiquet and Fambrough, 1984), 
hexabrachion (Erickson and Inglesias, 1984) or J1 glycoprotein (Kruse et al., 1985).
        Proteoglycans are specialized components of the ECM and are made 
of glycosaminoglycans (GAGs) building blocks. The GAGs are very long un-branched 
chains of disaccharide amino sugars. There are six groups of GAGs, and each has a 
characteristic biochemical composition. The GAG chains are linked to a “core protein” 
which in turn is linked via a “link protein” to a backbone of hyaluronan. The biological 
functions, and altered expression in tumours of proteoglycans are discussed in Chapter 
2.
Aim and outline of the thesis 
The major aim of thesis was to investigate the role of stromal cells and various extracellular 
matrix (ECM) molecules in canine tumour progression. In Chapter 2, the possible role 
of tenascin and proteoglycans in canine tumours are reviewed. In Chapter 3, the type 
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and origin of stromal cells present in the normal canine gut mucosa, and those in gut 
epithelial tumours are outlined. We also investigated the temporal and spatial expression 
of tenascin-C (an extracellular matrix onco-foetal ECM protein), and its co-localisation 
with myofibroblasts in canine epithelial gastrointestinal (GIT) tumours.  In vitro 
experiments have demonstrated that tenascin-C induces cell proliferation; therefore, in 
Chapter 4, the relationship between tenascin-C expression and tumour cell proliferation 
in vivo are studied. In Chapter 5, the expression of other ECM molecules (chondroitin 
sulphate, versican and hyaluronan) in colonic adenomas and carcinomas, and their 
relation to malignancy are discussed. In Chapter 6, a review on the immunobiology 
and progression of the canine transmissible venereal tumour (CTVT), and the possible 
role of stromal cells and ECM molecules in the spontaneous regression of this tumour 
is given. In Chapter 7, the type of stromal cells (fibroblasts and myofibroblasts) 
and the temporal expression of ECM proteins (tenascin-C, hyaluronan, chondroitin 
sulphate and versican) during progression and regression of CTVT are investigated. 
  To compliment the descriptive immunohistochemical studies with 
a functional investigation, in Chapter 8, using in vitro experiments some of the 
mechanisms involved in the modulation of stromal cell phenotype and secretion of 
ECM molecules in tumours by co-culturing tumour and stromal cells are investigated. 
  From the results of the immunohistochemical studies and the cell 
culture model study, together with recent literature data, in Chapter 9 a graphical model 
on the modulation of the tumour microenvironment (stromal cells and ECM) by tumour 
cells, and how the changes in the environment influence tumour progression is given.
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Abstract
Tenascin is a high molecular weight extracellular matrix glycoprotein, subject to complex 
spatial and temporal patterns of expression during embryogenesis, wound healing and 
neoplastic processes. Proteoglycans are complex macromolecules containing one or 
more glycosaminoglycans attached to a core protein. They are involved in cell-cell 
interaction. Altered expression of both tenascin and proteoglycans has been found in 
tumours and expression of these two extracellular matrix proteins seems to be modulated 
in the same way in human and canine tumours. The quantitative and qualitative changes 
in tenascin and proteoglycan composition may significantly affect behaviour of 
tumour cells. While tenascin and proteoglycans have many biological functions likely 
to influence tumour development and progression, their exact role in regulation of 
tumour cell-cell proliferation, invasion and metastasis remains to be established. This 
review focuses on the role of tenascin and proteoglycans in tumourigenesis and recent 
developments in canine tumours.
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Introduction
The extracellular matrix (ECM) is a dynamic, intricate network of macromolecules that 
plays an important role in regulating cellular function during normal and pathological 
remodelling processes, such as embryonic development, tissue repair, inflammation, 
and tumourigenesis. The ECM is linked to the plasma membrane and can deliver its 
instructions through membrane receptors, ultimately influencing gene expression, 
and as a consequence cell differentiation. The ECM contains mainly collagens, non-
collagenous glycoproteins and proteoglycans, but its composition is probably unique 
for each cell type within an organ.
  Histomorphogenesis during development of neoplastic processes is 
regulated at the genetic level, but modulated by the extracellular microenvironment 
where various components may play a role in cell growth and differentiation. In tumours 
an altered ECM is present. Elucidation of its components and the mechanism underlying 
the interaction of the ECM and cells could have profound impact on modulating 
tumourigenicity, and developing effective therapeutic intervention in cancer treatment.  
  The most extensively studied non-collagenous glycoproteins of the 
ECM are fibronectin and laminin. Unlike other ECM glycoproteins, tenascin appears 
in limited areas, at specific times. Tenascin is expressed during embryogenesis and 
induced in wound healing and neoplastic processes. Because of its spatio-temporally-
restricted distribution pattern, tenascin has attracted the attention of many researchers 
who suspect that it is an essential molecule in tumour cell-matrix interactions.
  Proteoglycans are a diverse group of proteins grouped together because 
of their glycosaminoglycan side chains. Previously, proteoglycans were considered as 
inert macromolecules, but now they are considered as dynamic components, which play 
a role in tumourigenesis. In several pathological processes such as inflammation, wound 
healing and tumours, there is alteration of both tenascin and proteoglycans, and these 
molecules seem to be modulated in the same way in canine tumours. Therefore, we 
found it necessary to discuss these molecules together in this review.
Cancer is a major cause of dog mortality. In one study, 45% of dogs that lived to ten 
years or older died of cancer (Bronson 1982). In general, dogs develop similar tumours 
at sites very analogous to those in humans, but it is worth separating studies on the 
pathogenesis of these tumours for the following reasons. Compared to man, dogs 
develop tumours twice as frequently (MacEwen 1989). Most canine tumours progress 
at a more rapid rate than in humans (Glickman and Domanski, 1986). Therefore, 
tumourigenesis and biological behaviour of canine malignancies should be different 
from those seen in humans. 
  The aim of this paper is to review the current knowledge of the 
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structure, localisation and function of tenascin and proteoglycans in normal tissues and 
in vitro systems. Then we will focus on the role of tenascin and proteoglycans in canine 
tumourigenesis and some of the mechanisms by which tumour cells modulate tenascin 
and proteoglycan expression.
Tenascin
Tenascin; structure and biologic function
Tenascin was first described and characterised in the 1980s from diverse sources by 
several independent groups. The term tenascin was introduced by Chiquet-Ehrismann 
(Chiquet-Ehrismann et al 1986) who put together the Latin verbs “ tenere” (to hold) and 
“nasci” (to be born). 
  Tenascin is a polymorphic, high molecular weight ECM hexameric 
glycoprotein composed of six sub-units joined together by a disulphide bond. The 
complete molecular structure has been elucidated (Siri et al 1991). The deduced amino 
acid structure shows that each of the six arms of tenascin is made u of four structural 
domains, cystein rich N-terminal portion involved in the hexamer formation, epidermal 
growth factor (EGF)- like repeats, variable number of fibronectin type III repeats and 
fibrinogen-like repeats.
  A single tenascin gene exists which undergoes alternative splicing 
at pre-mRNA level in the fibronectin- type III homologous region leading to many 
tenascin isoforms. Mechanisms regulating the splicing are based on developmental 
and pathological changes and on the cellular microenvironment, including pH changes 
(Kaplony et al 1991). The pre-mRNA undergoes alternative splicing to produce isoforms 
that have numerous potential N-linked glycosylation sites. Consequently, polymorphism 
of tenascin isoforms may originate from post-transcriptional modification of the 
polypeptide by sugars. It has been speculated that there is a difference in functions of 
the various tenascin isoforms.
  There are two possible functions of an ECM protein. The protein 
could serve a structural role within the ECM network, or it could be a modulator of 
cell function, implying the existence of direct interaction of this protein with cellular 
receptors. Both these possibilities have been proposed for tenascin. On the basis of 
several researches done, it can be deduced that tenascin is unlikely to perform a single 
specialised function, but as suggested by its multi-branched flexible structure, may 
perform a number of distinct functions in normal and transformed tissues. A summary 
of the proposed cell biologic effects of tenascin, based on experimental data is presented 
in Table 1.
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The most important function of tenascin pertaining to tumourigenesis is growth 
promotion and cell adhesion. In vitro experiments with human mammary carcinoma cells 
have shown that tenascin promotes cell proliferation more than any other ECM protein 
(Chiquet-Erismann et al 1986). Contrary to this, and more recently, tenascin has been 
shown to inhibit keratinocyte growth in a dose dependent manner (Latijnhouwers et al 
1997). This anti-mitogenic effect of tenascin may be specific for epidermal cells or tenascin 
may inhibit proliferation, thereby stimulating migration in order to facilitate invasion. 
Further characterisation of the mechanism of growth promotion or inhibition is needed.
  It has been shown that mammary carcinoma cells react to exogenous 
tenascin by losing cell-cell and cell-substrate contacts (Chiquet-Ehrismann et al 1989). 
In this model tenascin was able to promote the release of single cells from epithelial cell 
sheets in vitro; therefore, it could possibly also aid cells to leave an original tumour in 
vivo allowing them to invade the surrounding tissues, and ultimately metastasize.
 
Tenascin in development
Epithelial-mesenchymal interaction is fundamental for normal embryogenesis of 
numerous organs. In the developing embryo, tenascin is expressed mainly at the 
interface between stromal and epithelial components (Chiquet-Ehrismann et al 1986) 
and in developing neuronal tissue, cartilage and bone (Mackie et al 1987), i.e. regions of 
TABLE 1. Biological effects of Tenascin       
Function References
Hemagglutination Erickson and Inglesias 1984 
Neuron-glia adhesion Kruse et al 1985
Growth inhibition Latijnhouwers et al 1997
Inhibition of cell attachment Chiquet-Ehrismann et al 1988
Promotion of chondrogenesis Mackie et al 1987
Guidance of neural crest cell 
migration 
Halfter et al 1989
Inhibition of epithelial cell-cell 
contact
Chiquet-Ehrismann et al 1989
Immunomodulation Hemesath et al 1994 
Regulation of gene expression Tremble et al 1994
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morphogenic movement and tissue organisation. Aufderheide and Ekblom (1988) found 
that during gut development, tenascin appeared in the mesenchyme when the homologous 
endodermal epithelium differentiated into the heterologous epithelium. There is 
therefore a strong indication that peri-epithelial stromal tenascin is probably associated 
with the modulation of stromal-epithelial interactions during tissue remodelling.
  In adult tissues, the distribution of tenascin is more restricted, the 
expression being more enhanced only in tissues undergoing repair and remodelling 
(Natali et al 1991). In normal adult tissues, the presence of tenascin in sub-endothelial 
matrix suggests that tenascin may play a modulating role in transvascular migration, 
as inferable from its function in embryonic migration. The reduction of tenascin to 
the point of disappearance in adult tissues may result from lack of tenascin mRNA 
transcription due to either the presence of repressor molecules, or the absence of 
transcription initiation factors.  
  Some controversy surrounds the function of tenascin in embryonic 
development. Transgenic mice, in which the tenascin gene was deleted and replaced by 
an unrelated gene developed normally (Saga et al 1992) in the absence of tenascin, and 
produced viable offspring without tenascin. However, this did not meet much interest 
because of the following reasons:
1. Other molecule(s) may have compensated for the function of tenascin. In fact it is 
difficult to demonstrate any active biological function of purified tenascin. 
2. Another tenascin gene family may exist. In order to get the gene function in gene 
disrupted animals correctly, there is need to get rid of any influence of the difference in 
mouse genetic background. 
3. An appropriate test may not have been chosen to highlight the selective advantage of 
tenascin, and minor phenotypic changes might have remained unnoticed. For example 
decreased cell proliferation and cytokine expression were observed in injured glomeruli 
of tenascin knockout mice (Jyo et al 1997).
Tenascin in wound healing  
Tenascin is induced in wound healing, a process where cells themselves are exerting 
forces into the surrounding ECM, and thereby rearranging it. Mackie et al (1988a) 
examined the distribution of tenascin in normal and healing skin wounds in rats and 
showed that tenascin was sparsely distributed only in association with basement 
membrane in normal skin. In wounds and granulation tissue, there was a marked increase 
in the expression of tenascin. A marked increase of tenascin expression was found 
beneath migrating keratinocytes in human skin wounds (Latijnhouwers et al 1996). 
These findings suggest that tenascin might be a substrate of migrating keratinocytes. 
- Tenascin and Proteoglycans in Canine Tumours - 
26
- Chapter 2 -
27
Tenascin in canine tumours
Examination of a variety of human tumours by anti-tenascin antibody 
immunohistochemistry has shown an enhanced expression of tenascin in both 
malignant and benign tumours (Koukoulis et al 1991). In tumours of domestic animals, 
very limited work has been done on tenascin expression. As far as we know, only two 
published researches have been done in tumours of domestic animals. These studies 
were done on canine mammary tumours (Arai et al 1994, Faustino et al, in press). 
Arai et al (1994) studied a limited number of tumours and concentrated on tenascin 
expression in chondroid metastatic processes. We demonstrated the presence of tenascin 
in canine mammary tissues, with an increased expression in situations of remodelling 
and neoplastic lesions (Faustino et al, 2002). However, there was no difference of 
tenascin pattern in benign and malignant tumours and therefore, we concluded that 
tenascin cannot be used as a marker for transformation or malignancy. Where as 
tenascin cannot be used as a reliable marker for malignancy in canine mammary 
tumours, its variable distribution in hyperplastic canine mammary glands and tumours 
merits further studies.
  Ongoing studies at our institute have shown that tenascin expression in 
canine epithelial tumours of the gut is increased with a typical pattern (Mukaratirwa et al 
2003). Examination of more tumours of the whole gastrointestinal tract and metastases to 
regional lymph nodes and other organs is needed to get a clear pattern of tenascin expression. 
  Research must be done on other important tumours like melanocytic 
and prostate tumours of which the behaviour is different from the human counterparts. 
In human prostate cancer, Xue et al (1998) demonstrated that tenascin might be used as 
a pre-malignant marker of prostatic lesions. Research is needed to determine whether 
tenascin can be used as a progression marker in canine prostate tumours. Melanocytic 
tumours are common in dogs and horses. They are formed from melanoblasts and, 
these cells are of neural crest origin. The distribution of tenascin has been shown to 
coincide with pathways of neural crest cell migration (Mackie et al 1988b), and in vitro 
experiments have shown that tenascin increases the rate of neural crest cell migration 
from neural tube explants (Halfter et al 1989). Tenascin expression pattern of these 
tumours might be different from mesenchymal and epithelial tumours. In summary, it 
is apparent that altered tenascin expression is present in canine tumours, but a lot more 
research has to be done on the patterns of expression and its significance.
- Tenascin and Proteoglycans in Canine Tumours - 
28
- Chapter 2 -
29
Proteoglycans
Proteoglycans: structure and nomenclature
Proteoglycans are macromolecules that contain one or more glycosaminoglycans 
(GAGs) covalently attached to a core protein to yield a brush-like appearance. The 
GAG component is variable in structure and size, and usually dominates the physical 
behaviour of proteoglycans. A comprehensive review of each GAG falls beyond the 
scope of this paper. 
  The nomenclature of proteoglycans is confusing and subject to 
debate. In previous years, proteoglycans were given a name, which reflect the source 
of glycosylation, e.g., basement membrane heparin sulphate proteoglycan and large 
aggregating chondroitin sulphate proteoglycan of cartilage. An alternative scheme in 
which attention is given to the nature of glycosylation has been suggested. However, 
this scheme has encountered many problems because a single proteoglycan can be 
glycosylated by more than one GAG. For example, aggrecan is glycosylated by both 
keratan and chondroitin sulphate.
  In recent years, the ability of molecular techniques to isolate and 
sequence the DNA from which the core protein is transcribed has led to a naming 
based on structural features of the core protein, the primary gene product. Examples are 
decorin (Krusius and Rouslahti 1986), which decorates collagen fibril, and fibromodulin 
(Oldberg et al 1989), which modulates the formation of collagen fibrils.
Proteoglycans: biological functions
The functions of proteoglycans are not well understood like those of tenascin. However, 
results derived from studies of mutant animals indicate that certain proteoglycans are 
essential to life where as others might be redundant (Iozzo 1998). The specific functions 
of individual proteoglycans vary greatly because of diversity of the structure of core 
proteins, but they have a general propensity to be involved in cell adhesion phenomena. 
Some of the proposed biological functions of proteoglycans are shown in Table 2. 
Proteoglycans in canine tumours  
The connective tissue stroma of benign or malignant tumours is a newly formed tissue 
that supports growth and progression of tumour cells. Proteoglycans are the main 
components of the stroma, and molecular and structural changes of these molecules 
can significantly affect behavioural properties of transformed cells. In early years 
proteoglycans were viewed as a non- specific response to growing tumour cells, and 
thus, passive bystanders. Recently, a large body of evidence (Hauptamann et al 1995) 
indicates that the tumour matrix plays a critical role in tumour progression. 
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  Presence of altered proteoglycans composition in human tumours 
has been reported as early as 1939 (Meyer and Chaffee 1939). At present altered 
proteoglycan or GAG expression has been reported in a variety of human tumours. 
Human chondrosarcoma represents the main malignant mesenchymal tumour in 
which abnormal proteoglycans have been detected (Mankin et al 1980). Increased 
levels of chondroitin sulphate have been reported in murine and human carcinomas 
(Kojima et al 1982, Iozzo 1982). Attempts have been made to establish the relationship 
between abnormal proteoglycan production and tumour cell properties. However, 
this has been hampered mainly by the fact that there are no proteoglycan alterations 
shared by or common to all histogenetically different tumours (unlike tenascin), and 
relative inaccessibility of their core proteins for biochemical analysis. Moreover, since 
proteoglycans are tissue specific, it is likely that each tumour expresses an abnormal 
proteoglycan profile in comparison to its normal counterparts. 
  Unlike in human tumours, the distribution and expression pattern 
of proteoglycans has not been studied extensively in canine tumours. Studies on the 
composition and distribution of PGs in canine tumours started as early as early as 1979 
(Palmer and Monlux, 1979). These researchers demonstrated that complex mammary 
carcinomas are rich in GAGs. These tumours are reported to be less malignant than 
their simple counterparts (Misdorp et al 1999), implying the role of GAGs in tumour 
progression. From 1979 up to now very little research has been done in proteoglycan 
TABLE 2. Proposed Biological functions of Proteoglycans 
Proposed function Proteoglycan(s) Reference
Tissue organisation Fibromodulin Oldberg et al 1989
Cell growth and maturation 
of specialized tissues
Heparan sulfate 
proteoglycan
San Antonio et al 1987
Modulation of growth 
factor activities
Leuceine rich 
proteoglycans
Iozzo 1997
Cell adhesion
Chondroitin sulfate 
proteoglycans,
Rouslahti 1988
Tumor cell growth and 
invasion
Chondroitin sulfate 
proteoglycans
Hanekamp et al 1998
Corneal transparency
Keratan sulphate 
proteoglycans
Hassel et al 1980
Neurite outgrowth Versican Landolt et al 1995
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distribution and function in canine or animal tumours. Recently, with the advent of 
molecular biological techniques, studies on the distribution and role of PGs in canine 
tumours are picking up momentum. Studies are now being done using in vitro systems, 
immunohistochemistry and in situ hybridisation.
  In dogs, studies have been done in mammary tumours (Hinrichs et al 
1999). Novel studies are being conducted on the role distribution of PGs and GAG in 
gastrointestinal tumours at our institute. In addition, proteoglycan production has been 
studied in canine mastocytomas (Forsberg et al 1988), but this study focused only on 
structural features of the proteoglycans produced. In this paper, the discussion will be 
mainly in reference to canine mammary tumors. 
  Hinrichs et al (1999) studied the distribution pattern of chondroitin 
sulphate in canine mammary tumours in relation to benign or malignant behaviour 
using Alcian blue and anti-chondroitin sulphate antibodies. Chondroitin sulphate was 
the most predominant sulphated GAG. This is consistent with findings in human breast 
tumours. Accumulation of chondroitin sulphate is found mainly in the stroma around 
clusters of tumour cells suggesting an epithelial induced production of chondroitin 
sulphate by fibroblasts. However, not all tumour stromal junctions showed this intense 
staining, suggesting another mechanism of chondroitin sulphate production. One might 
speculate that tumour cells in different stages of differentiation or proliferation may be 
responsible for this pattern of chondroitin sulphate production.
  It is important to note that the anti-chondroitin sulphate antibodies 
do not allow one to detect individual proteoglycans. This can be accomplished with 
antibodies to the core proteins. However, the nature of proteoglycans involved in the 
increase in chondroitin sulphate in canine mammary tumours is not known. Ongoing 
studies at our institution have pointed out to versican/PGM. Versican, a member of the 
large aggregating chondroitin sulphate proteoglycan family is expressed in the stroma 
of canine mammary tumours (Erdelyi et al 2003). In human breast tumours, versican has 
also been shown to be increased (Nara et al 1997). In human colon tumours, versican 
is altered as a consequence of hypomethylation of its control genome regions (Adany 
and Iozzo 1990). The structure of the canine versican gene has not been elucidated, 
and studies on altered versican gene expression in canine tumours must been done to 
compare it with human tumours. Other chondroitin sulphate proteoglycans like decorin 
and biglycan can be responsible for the increase in chondroitin sulphate proteoglycans 
in canine mammary tumours, but have not been studied. Current studies of chondroitin 
sulphate in canine colon carcinomas at our institute have shown that chondroitin 
sulphate expression is increased in these tumours and their metastasis. 
  In summary it is apparent from these investigations that proteoglycans/
GAGs are altered in canine mammary and colon tumours. It is hoped that future studies 
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will be done on other canine tumours.
Induction and modulation of tenascin and proteogilycan synthesis in canine 
tumours
The principal cells of tumour stroma are fibroblasts, macrophages, lymphoid cells, 
mast cells and endothelial cells. Stromal cells produce most of the extracellular matrix 
components. The cellular source for the quantitative and qualitative changes of tenascin 
and proteoglycans is not clearly established, but several lines of evidence points to stromal 
origin. However, recent evidence has shown that epithelial cells can synthesise tenascin 
at least in vitro (Volmer et al 1997). Epithelial canine mammary tumour cells in vitro 
deposit chondriotin sulphate in a collagen gel either spontaneously or when stimulated 
by TGF-β (Hanekamp et al 1998). We have recently shown that there is granular 
cytoplasmic staining of tenascin in canine mammary tumour cells (Faustino et al 2002). 
These findings suggest that epithelial cells can synthesise ECM components in vivo.
  The precise modulation of tenascin and proteoglycans and other 
components is yet to be confirmed. Carcinoma cells in vitro synthesise a family of 
polypeptides that stimulate synthesis of chondroitin sulphate in fibroblasts (Iozzo 1985) 
and co-cultures of tumour cells with fibroblasts stimulate the production of hyaluronic 
acid (Merrilees and Finlay 1995). From these findings it is reasonable to assume that 
modulation of the extracellular matrix component biosynthesis is mediated by cytokines 
or cell-cell contact. Finally, some tumour cell lines release proteins that confer a 
transformed phenotype of fibroblast known as myofibroblast (Ronnov-Jenssen et al 
1993). Of the cytokines studied TGF-β is the most likely candidate. TGF-β, a tumour 
growth modifier, has many biologic effects. One important effect is the production and 
structuring of the extracellular matrix. TGF-β stimulates the synthesis of tenascin and 
proteoglycans (Bassols et al 1988, Chiquet-Ehrismann et al 1989). In addition TGF-β is 
a component of the extracellular matrix (Taipale et al 1994).
  If the observed results are representative of conditions in vivo, it is 
reasonable to come up with a model, where tenascin and proteoglycan modulation is 
regulated by tumour-host cell interactions. In this model, the tumour cell modulates 
tenascin and proteoglycan synthesis directly or indirectly by releasing TGF-β and 
other growth factors. TGF-β either stimulates fibroblasts to produce tenascin and 
proteoglycans or modifies the phenotype of fibroblasts to myofibroblasts, which then 
synthesise tenascin and proteoglycans. An autocrine stimulation of tumour cells by 
TGF-β to produce tenascin and proteoglycans is also possible. In addition, TGF-β may 
inhibit the degradation of extracellular matrix by stimulating the synthesis of protease 
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inhibitors (Laiho et al 1986), and decreasing the synthesis of proteases (Chiang and 
Nilsen-Namilton 1986), thereby, favouring the accumulation of matrix proteins. 
Immunocompetent cells like macrophages, when present, might modify tenascin 
and proteoglycan directly or indirectly through a number of signals: stimulation of 
fibroblasts growth, stimulation of connective tissue degradation or synthesis in the 
fibroblasts, and cytolytic effect on tumour cell.
  Other growth factors and cytokines produced by tumour or host cells 
may play a role in tenascin and proteoglycan regulation. Several growth factors and 
cytokines including NGF, PDGF, EGF, TNF-α and IL-4 have been shown to affect 
tenascin and proteoglycan expression by cultured cells, but the effect in vivo has not 
been studied. TGF-β and other growth factors may regulate tenascin and proteoglycan 
expression by modulating promoter activity of the tenascin gene. The intracellular 
signalling cascades leading to modulation of tenascin and proteoglycans is still 
elusive.
Conclusion and perspectives
The relationship between ECM and tumourigenesis is complex. Although no ECM 
molecule has yet been discovered as a cancer related product, the discovery of tenascin 
has introduced us to a new field of tumour biology. It is unequivocal that tenascin plays 
a role in tumourigenesis. Research on tenascin function and distribution in tumours has 
been going on since its discovery in 1983. Many conclusions, suggestions, hypotheses, 
and theories have been drawn on tenascin function, but there are still many questions 
with no clear answers: How is tenascin expression regulated? How is alternative splicing 
regulated and is there significance in function of different isomers? How does tenascin 
exert its function – cellular receptors or secondary messengers or interaction with other 
molecules? Which stromal cells are associated with tenascin production? What is the 
relationship between tenascin and cell proliferation markers like Ki-67?  Is tenascin 
expression related to loss of trans-membrane adhesion molecules like cadherins and 
catenins? Answering some of these questions might help coming up with a conclusion 
on the function of tenascin in tumourigenesisis. 
  Although proteoglycans are not expressed in a spatially or temporally 
restricted manner like tenascin, evidence presented above suggests that there is altered 
expression in canine tumours. More studies have to be done. One of the difficulties in 
studying proteoglycans in canine tumours is the use of antibodies against human core 
proteins. Nevertheless, some human antibodies are known to cross react with canine 
tissues. Further research is required on proteoglycan expression in various canine 
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tumours, because a large number of questions still remain unanswered; for example: Are 
there any tumour specific proteoglycans? Is altered proteoglycan expression in canine 
tumours comparable to that in human tumours? How does the tumour cell modulate 
proteoglycan synthesis and assembly, and what is the role of cytokines like TGF-β? 
With the availability of specific antibodies, and the development of efficient isolation of 
proteoglycans, it seems that answers to many of these questions will become available 
in the near future.
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Abstract  
The expression of tenascin, α-smooth muscle actin (α-SMA), desmin and vimentin was 
investigatedimmunohistochemically in the stroma of  normal canine stomach, small 
intestine and colon, and in30 epithelial tumours of the canine stomach, small intestine 
and colon by immunohistochemistry. In addition, “co-localisation” of tenascin and α-
SMA was investigated by double immunohistochemistry. Tenascin was absent in the 
normal mucosa of the stomach, but expressed in the normal intestine with a gradual 
increase from the cryptal glands to the surface epithelium. Tenascin expression was 
greater in all adenomas and carcinomas. Two different patterns of tenascin expression 
were observed in carcinomas, irrespective of their site. In well-differentiated tumour 
regions of both gastric and intestinal tumours, a fibrillary sub-glandular expression 
was observed; in poorly differentiated tumour regions, however a diffuse network 
expression pattern was present. Incomplete invasion of the muscularis mucosae was 
accompanied by thickening and increased tenascin expression. In normal stomach and 
small intestines, α-SMA and desmin were demonstrated in pericryptal myofibroblasts 
and smooth muscle cells of the muscle layers. In colonic adenomas and gastric and 
intestinal carcinomas, α-SMA was demonstrated in all stromal cells surrounding 
tumour cells. In contrast to α-SMA labelling, desmin labelling was negative in tumour 
stromal cells (in both gastric and intestinal tumours), except in tumour regions close to 
the muscularis mucosae. This suggest that myofibroblasts in gastrointestinal tumours 
originate from pre-existing fibroblasts except in tumour regions close to the muscularis 
mucosae, where the myofibroblasts seem to originate from smooth muscle cells of 
the muscularis mucosae. There was a strong co-localisation of tenascin and α-SMA 
expressing myofibroblasts suggesting that myofibroblasts may be responsible for 
tenascin secretion.
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Introduction  
Tenascin is an extracellular matrix glycoprotein that has been shown to have an 
influence on cell adhesion, growth, proliferation and differentiation (reviewed by 
Chiquet-Ehrismann et al., 1995). The type of cell producing tenascin in tumours in 
vivo is not clear. Many researchers have pointed to mesenchymal cells like fibroblasts, 
smooth muscle cells and glial cells as the main producers of tenascin in vivo (Mackie, 
1995) that are thought to be under the influence of cytokines produced by epithelial 
tumour cells (Jones and Jones, 2000).
  Pathological conditions associated with tissue remodelling are 
characterised by the appearance of stromal cells with ultrastructural features intermediate 
between those of typical fibroblasts and those of smooth muscle cells; they were first 
described in granulation tissue and were called myofibroblasts (Gabbiani et al., 1971). 
Myofibroblasts expressing α-smooth muscle actin (α-SMA) have been considered the 
most significant single stromal cell type in epithelial tumours of the colon (Sappino et 
al., 1989).  In human mammary (Sappino et al., 1988) and ovarian (Czernobilsky et al., 
1989) tumours α-SMA-expressing myofibroblasts have been found in the stroma  of the 
tumours. The origin of myofibroblasts in colonic epithelial tumours is not clear. They 
may arise from pre-existing fibroblasts of stroma and pericryptal areas, or from smooth 
muscle cells of the muscularis mucosae and blood vessels. Pre-existing fibroblasts are 
likely candidates; this opinion is based on the finding of stimulation of stromal fibroblasts 
in vitro, mediated through various pathways of signalling by cytokines such as TGF-β 
has been shown to induce α-SMA expression in cultured fibroblasts (Desmoulié et al., 
1993; Rô nov-Jessen and Petersen, 1993). In addition, fibroblastic cells have been found 
to express features of muscle differentiation in diverse pathological conditions (Skalli et 
al., 1989b), in which modulations of the peritumoural extracellular matrix coincide with 
proliferative characteristics of tumour tissues (Sappino et al., 1988). 
  Accumulation of tenascin has been demonstrated in the stroma of 
many human mammary adenomas and carcinomas (Koukoulis et al., 1991). In human 
endometrial tumours, tenascin was identified in periglandular location in cases in which 
α-SMA was also present (Czernobilsky et al., 1993). Tenascin mRNA been has found to 
be expressed by myofibroblasts in human colon adenomas and carcinomas (Hanamura 
et al., 1997). The precise function of myofibroblasts in tumours is not fully understood, 
but their restricted distribution and association with tenascin point to their function 
in tissue reorganisation processes in ovarian follicles, intestinal mucosa and tumours 
(Czernobilsky et al., 1993).
  The relationship between tenascin expression and phenotye of stromal 
cells in human and canine intestinal tumours is not clear. The aims of the present study 
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were to study (1) the expression pattern of tenascin and α-SMA in normal and neoplastic 
conditions of the canine stomach, small intestine and colon, (2) the co-localisation of 
tenascin and α-SMA expressing myofibroblasts in such neop[lastic tissues, and (3) the 
expression of desmin and vimentin in relation to α-SMA in the stroma of tumours, to 
elucidate the origin of the α-SMA expressing myofibroblasts. 
Materials and methods  
Case material
Cases of canine gastrointestinal adenomas (n=11), adenocarcinomas (n=14) and 
anaplastic carcinomas (n=5) were selected from the files of the Department of Pathology, 
Faculty of Veterinary Medicine, Utrecht University. Details of the localizations of the 
various tumours and their numbers are given in table 1. In addition, full thickness 
samples of normal canine stomach (n=10), small intestine (n=10) and colon (n=10) 
were obtained. Haematoxylin and eosin-stained sections were made to confirm the 
original diagnosis made by the pathologists of our department; the tumours were 
classified according to the WHO classification of tumours of the lower alimentary tract 
(Head, 1976)
Table 1. Summary of the number of tumours studied.
Tumour Stomach Small 
intestine
Colon Rectum Total
Adenoma
     Tubular
     Tubulovillous
0
0
0
0
1
2
2
6
3
8
Adenocarcinoma
      Mucinous
      Tubular
       Solid/ signet ring 
3
3
0
0
3
1
2
1
1
0
0
0
5
7
2
Anaplastic Carcinoma 3 2 0 0 5
Total 9 6 7 8 30
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Immunohistochemistry
Representatives of each tumour and normal tissue were selected for immunohistochemical 
analysis of tenascin, α-SMA, desmin and vimentin. In each case, 4-μm sections 
of formalin-fixed, paraffin wax-embedded tissues were mounted on poly-L-lysine 
coated slides. The slides were de-waxed through xylol and graded alcohols. Sections 
to be labelled for tenascin were incubated with chondroitinase AC (Sigma, St Louis, 
MO, USA) at a concentration of 2 units/ml in 0.25M Tris/HCl buffer (pH 8) at 37oC 
overnight to reduce antigenic masking of tenascin by chondroitin sulphate (Faustino et 
al., 2002). For tenascin retrieval, antigen was unmasked by treatment for 10 minutes 
at 37oC with trypsin 0.1% in PBS containing CaCl
2 
0.1% (0.01M, pH 7.4) at a final 
pH of 7.8. Endogenous peroxidase activity was blocked by H
2
O
2
 0.3% in PBS for 30 
minutes. After incubation with normal horse serum diluted 1 in 10 for 30 minutes to 
block background staining, the sections were treated with primary antibodies at room 
temperature for 60 minutes. The antibodies used were against tenascin (clone TN2; 
Dako, Glostrup, Denmark) at a dilution of 1 in 50, α-SMA (clone 1A4; Biogenex, 
CA, USA) at a dilution of 1 in 1200, vimentin (Clone V9; Biogenex) at a dilution 
of 1 in 150 and desmin (RD 301; Euro Diagnostic B.V., The Netherlands) undiluted. 
After incubation with horse anti-mouse biotin and avidin-biotin peroxidase complex 
(Vector, Burlingame, USA), the colour was developed in 3-3’-diaminobenzidine and 
0.02% H
2
O
2
 in Tris buffer pH 7.8. The sections were counter-stained with 10% Mayer’s 
haematoxylin. The muscularis mucosae was used as internal positive control. For 
negative controls, the primary antibodies were replaced with normal mouse serum.
Double staining immunohistochemistry
A double immunohistochemical procedure based on a sequential technique (van der 
Loos, 1999) was performed to establish the co-localisation of tenascin and α-SMA 
expressing myofibroblasts. The staining procedure started with tenascin primary 
antibody but without developing the enzymatic activity followed by α-SMA antibody. 
The sections were treated with chondroitinase AC and tenascin retrieval was performed 
as explained above. The sections were incubated with normal horse serum 10% for 20 
minutes followed by tenascin antibody (Clone TN2; Dako) for 60 minutes and horse 
anti-mouse biotin (Vector) for 30 minutes diluted as above. For α-SMA assay, the first 
part of the double staining consisted of blocking the first antibody by incubating with 
goat anti-mouse immunoglobulin (Dako) at dilution of 1 in 50 for 50 minutes and then 
incubation with α-SMA (Clone 1A4; Biogenex) at a dilution of 1 in 1200 overnight at 
4oC. Incubation with a mixture of goat anti-mouse immunoglobulin alkaline phosphatase 
(AP; Dako) at a dilution of 1 in 300 and streptavidin horse-radish peroxidase (HRP; 
Dako) at a dilution of 1in 50 followed this. The enzymatic activities of AP and HRP 
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were visualised in blue with 5-bromo-4-chloro-3-indoxyl phosphate and nitro blue 
tetrazolium chloride (BCIP/NBT; Dako), and red with 3-amino-9-ethylcarbazole (AEC; 
Dako) respectively. No counterstaining was performed, and slides were mounted with 
paramount (Dako).
Results   
Table 1 contains a summary of the tumours examined. All the adenomas were from the 
colon or the rectum, whereas the carcinomas involved tumours from stomach and small 
intestine as well.. Table 2 summarises the expression of tenascin and α-SMA in normal 
gastrointestinal tissues, primary tumours and mesenteric lymph node metastases.
Tenascin expression
Normal tissues. In normal adult stomach tenascin was not expressed in the mucosa 
Table 2. Tenascin and α-smooth muscle expression in normal mucosa and 
tumours and lymph node metastasis
Tissue Tenascin α-SMA
Normal stomach
              small intestine
              colon
Adenomas
Adenocarcinomas
Anaplastic carcinoma
Metastatic tumour
0/10∗
10/10
10/10
10/11
12/14
5/5
2/4
10/10
10/10
10/10
11/11
14/14
5/5
4/4
∗Numerator, number of positives; denominator, number examinned.
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even at the epithelial-mesenchymal interface. Tenascin was strongly expressed in the 
extracellular matrix of the muscularis mucosae and muscularis propria and in the cells 
themselves. In the submucosa and serosa there was no tenascin expression except in the 
media of muscular arteries. 
  In normal small intestine, tenascin was expressed in areas adjacent to the 
basement membrane. Expression was increased from the crypts to the villi with abundant 
expression at the top of the villi. Transverse section of the villi showed a thin continuous 
line at the base of the epithelium representing the basement membrane. Labelling of 
tenascin in the normal colon was similar to that in the small intestine with an increased 
expression from the glands to the surface of the mucosa. At the apical portion of the 
mucosa, a sparse network of tenascin immunolabelling was present (Fig. 1). Granular 
cytoplasmic labelling was seen in some epithelial cells of the stomach, small intestine 
and colon. Tenascin was not expressed in the submucosa and serosa except around 
submucosal (Brunner’s) glands and media of muscular blood vessels. In smooth muscle 
areas (muscularis mucosae and muscularis propria) tenascin was constantly expressed.
Adenomas. 
In 10 adenomas, tenascin was expressed when stroma was present (Fig. 2). Expression 
Fig. 1. Normal colon immunolabelled for tenascin. 
Sparse network-like immunoreaction of tenascin at the 
apical portion of the mucosa. Avidin-biotin peroxidase 
complex (ABC), haematoxylin counter-stain. x 400
Fig. 2. Colorectal adenoma immunolabelled for 
tenascin. Increased tenascin immunoreactivity in the 
tumour stroma and cytoplasmic granular staining in 
tumour cells. ABC, haematoxylin counter-stain. x 200
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of tenascin at the tip of adenomatous growth was intense and greatly exceeded that in 
normal mucosa. Granular staining of tenascin in the cytoplasm of tumour cells was seen 
in four cases (Fig. 2). There was no relation between cytoplasmic labelling of tenascin 
and the intensity of extracellular expression.
  Alteration in the thickness of muscularis mucosae and tenascin 
expression was seen in eight of the tumours where the adenoma was near or in contact 
with the muscularis mucosae. In these cases the thickness of muscularis mucosae 
changed from a regular line into an outgrowing mass filling the base of the tumour with 
filamentous pattern of tenascin-positive stroma projecting into the adenomatous growth. 
In cases where the tumour was growing from the top of the normal mucosa, there 
was increased expression of tenascin at the junction of tumour and normal mucosa, 
suggesting that the tumour was founded on this tenascin positive base. The submucosa, 
muscularis propria and serosa showed the same pattern as the normal tissue.
Adenocarcinomas. 
  Samples of 14 adenocarcinomas were examined. Twelve cases had 
tumour proliferation in the mucosa and tenascin was expressed when stroma was 
present. In two cases the stroma was completely negative for tenascin but there was 
granular cytoplasmic labelling of tumour cells (Fig. 3). Cytoplasmic granular staining 
of tenascin was seen in three other adenocarcinomas. 
  Eight cases had invasion into the muscularis mucosae. In these cases 
two different patterns were observed. When incomplete invasion was present the 
muscularis mucosae was thickened with intense expression of tenascin and tenascin 
positive stromal projections completely surrounding invading tumour cells, as in the 
adenomas. When complete invasion was present, there was a break in the muscularis 
mucosae by tumour cell-containg lymphe vessels; some tenascin expression was found 
around these vessels (Fig. 4), but deeper in the submucosa tenascin expression around 
these vessels was frequently absent. In 12 cases there was invasion into the submucosa, 
Fig. 3. Gastric adenocarcinoma immunolabelled for 
tenascin. Cytoplasmic granular labelling of tenascin 
in tumour cells and negative tumour stroma. ABC, 
hematoxylin counter-stain. x 200
44
- Tenascin in Canine Gastrointestinal Tumours -
45
- Chapter 3 -
muscularis propria and serosa. The expression pattern of tenascin seen in these regions 
was significantly different, even within the same tumour, depending on the degree of 
differentiation and site of invasion. In general two patterns were observed. In well-
differentiated tumour regions with gland or cyst formation, the immunoreactivity, 
which was fibrillary, was subglandular or located in the basement membrane (Fig. 5). 
In poorly differentiated tumour regions, a more diffuse, net-like expression was present 
(Fig. 6). In the tumour stroma, tenascin expression was less in the submucosa than in the 
muscularis propria and serosa. In the submucosa, labelling varied according to the depth 
of invasion. Stroma of tumour regions near muscularis mucosae was always positive 
for tenascin and the stroma seemed to be connected to the muscularis mucosae. Tumour 
regions deep in the submucosa were always negative. 
Anaplastic carcinomas. 
  The same pattern of tenascin expression was found as in poorly 
differentiated regions of adenocarcinomas. In all the cases there was invasion into the 
submucosa, but tenascin was expressed in only two cases (of  small intestinal origin), 
Fig. 4. Jejunum adenocarcinoma immunolabelled 
for tenascin. A break of the muscularis mucosae and 
decreased tenascin immunoreactivity at the invasion 
front. ABC, haematoxylin counter-stain. x 100
Fig. 5. Colon adenocarcinoma immunolabelled 
for tenascin. Fibrillary sub-glandular tenascin 
immunoreactivity around a well-differentiated tumour 
region. ABC, haematoxylin counter-stain. x 200
Fig. 6. Gastric adenocarcinoma immunolabelled for 
tenascin. Diffuse netlike tenascin immunoreactivity 
in a poorly differentiated tumour region in the serosa. 
ABC, haematoxylin counter-stain. x 200 (refer to 
colour picture page 156)
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although there was abundant stroma (desmoplasia) in these tumours. 
Lymph node metastasis. Four cases with mesenteric lymph node metastasis were 
examined. In all the four cases tenascin was expressed in the primary tumour. In two 
cases tenascin was expressed in the metastasis.
α-smooth Muscle Actin, Desmin and Vimentin Expression
Normal tissue. α-SMA was expressed in different muscular layers of the stomach, small 
intestine and colon, and in the media of muscular vessels and pericytes. Pericryptal 
fibroblasts at the bases of the crypts were also positive for α-SMA. The stromal cells in 
the submucosa and serosa were completely negative. Desmin showed the same pattern 
of expression as α-SMA. All stromal cells were positive for vimentin. 
Adenomas. 
In nine adenomas a persistent sheath of α-SMA positive cells was found bordering the 
epithelia, and labelling was also observed in foci of stromal cells within the tumour. In 
contrasts, however, none of the adenomas examined expressed desmin in the tumour 
stroma, except in areas close to the muscularis mucosae. In such areas, the desmin-
positive tumour stromal cells seemed to be connected to the muscularis mucosae.
Adenocarcinoma. 
The 14 cases of adenocarcinomas examined showed no evidence of α-SMA in the 
pericryptal fibroblasts in the mucosa. However, foci of stromal cells representing 
desmoplastic reaction were positive for α-SMA. At the point of muscularis mucosae 
invasion the intensity of α-SMA expression was increased. In the submucosa stromal 
cells of the tumour were positive when close to the muscularis mucosae, but as with 
tenascin labelling, less strongly when in the submucosa. The stroma of tumour nests in 
the muscularis propria and serosa was positive for α-SMA (Fig. 7).
  When the tumour was present in the mucosa, desmin was not expressed 
Fig. 7. Colon adenocarcinoma with invasion into the 
serosa immunolabelled for α-SMA. Tumour stromal 
cells are positive for α-SMA. ABC, haematoxylin 
counter-stain. x 200
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even in regions where α-SMA was positive. Stroma of tumour nests in the muscularis 
propria and serosa were negative for desmin. Interestingly, tumour regions in the 
submucosa close to the muscularis mucosa showed intensely desmin-positive stromal 
cells, while stromal cells deep in the submucosa were negative for desmin, even when 
they were positive for α-SMA. 
Carcinomas. 
The same pattern of α-SMA actin and desmin expression was seen as in adenocarcinomas. 
In three cases (two gastric and one small intestine), α-SMA negative stromal cells 
surrounded individual carcinoma cells.
Co-localisation of and α-SmoothMuscle Actin
This was was evaluated by comparing serial sections labelled for tenascin and α-SMA 
and then confirmed by double labelling.
Normal tissue. 
In normal tissue tenascin was expressed mainly in conjunction with α-SMA expressing 
cells. Thus the muscularis mucosae and muscularis propria, which were strongly positive 
for α-SMA actin and appeared to be the major sites for tenascin expression. This area 
served as our internal positive control for the double labelling. In the gastric mucosa, 
there was no tenascin expression, but α-SMA was positive in cells surrounding glands. 
In the mucosa of small intestines and colon, there was co-localisation of tenascin and α-
SMA at the tips of the villi or surface epithelium. Double labelling showed that isolated 
stromal cells (representing smooth muscle cells) in the lamina propria co-expressed 
tenascin and α-SMA. However, pericryptal myofibroblasts surrounding glands close to 
muscularis mucosae were strongly positive for α-SMA but negative for tenascin.
Tumours. 
In the mucosa there was almost 100% co-localisation of tenascin and α-SMA. In three 
cases with desmoplasia, the stromal cells were positive for α-SMA, but negative for 
tenascin. In all cases tenascin was always expressed in conjunction with α-SMA positive 
cells. Within the same tumours there were regions where tenascin was not expressed, 
but α-SMA was expressed.
  Tenascin was strongly expressed in conjunction with α-SMA in 
the muscularis mucosae at the base of adenomas or areas of incomplete invasion 
in adenocarcinomas and anaplastic carcinomas. Stroma projecting from muscularis 
mucosae into the tumour was positive for both tenascin and α-SMA.
  Tumour regions in the submucosa, muscularis propria and serosa 
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showed a significant difference in the co-localisation of tenascin and α-SMA, depending 
on the location and degree of differentiation. In the submucosa, tumour regions close 
to the muscularis mucosae co-expressed tenascin and α-SMA, and those deeper were 
faintly positive for α-SMA actin and negative for tenascin. In well-differentiated tumour 
regions co-localisation was more evident (Fig. 8). Tumour regions in the muscularis 
propria and serosa showed strong co-localisation in eight cases, but there was variation 
within the same tumour. In some regions of the same tumour the stroma expressed both 
tenascin and α-SMA, but in some regions stromal cells were positive for α-SMA and 
negative for tenascin (Fig. 8). In no case was tenascin expressed in absence of α-SMA-
positive cells.
Fig. 8. Gastric adenocarcinoma double immunolabelled 
for tenascin and α-SMA. Co-localisation of tenascin 
and α-SMA in stroma surrounding well-differentiated 
tumour regions. Note some areas are positive for α-
SMA, but tenascin is not expressed. AEC and NBT/
BCIP, no counter-stain. x 200 (refer to colour picture 
page 156
Discussion   
There is increasing evidence that tumour stromal components play a role in 
tumourigenesis by modulating growth and differentiation. Increased tenascin expression 
has been documented in many human tumours (Koukoulis et al., 1991; Natali et al., 
1991) and in dog mammary tumours (Faustino et al., 2002), but no reports are available 
on tenascin expression in other canine tumours. Few studies on the type of stromal cells 
present in human gastrointestinal tumours have been published (Ohtani and Sasano, 
1983; Sappino et al., 1989), and there are no published studies on the origin and type 
of cells responsible for tenascin secretion in both human and canine gastrointestinal 
tumours.
  The present study showed that in the normal canine gastric mucosa 
tenascin expression was absent, whereas in the small intestine and colon tenascin was 
expressed at the epithelial-mesenchymal interface with a gradual increase from the 
crypts to the mucosal surface. The observations in the stomach are in line with the 
reported tenascin expression pattern in human stomach (Tiitta et al., 1994; Ikeda et al., 
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1995). The observations in the small intestine and those in the colon are in agreement 
with the reported tenascin expression pattern in human small intestine and colon (Reidl 
et al., 1992; Gulubova and Vlaykoya, 2001) and murine intestine (Thor et al., 1987). 
It appears paradoxical that tenascin immunoreactivity was not present at the epithelial-
mesenchymal interface in the normal stomach where the epithelium is also undergoing 
rapid renewal, yet it was present in the small intestine and colon. The differences in 
tenascin expression may be explained by the different functions of epithelial cells or the 
difference in the rate of migration and turnover of surface epithelium as suggested by 
Tiitta et al., (1994). Another reason for such a differential distribution of tenascin in the 
stomach may be that epithelial cells of the stomach are not able to produce cytokines 
like TGF-β that stimulate tenascin synthesis by stromal cells.
  The presence of tenascin granular cytoplasmic immunoreactivity in 
epithelial cells in both normal and tumour cells suggest that epithelial cells synthesise 
tenascin. Similar results have been found in canine mammary tumours (Faustino et al., 
2002) and human epithelial tumours,  including those of colorectal origin (Gulubova 
& Vlaykoya, 2001). In vitro experiments have shown that tenascin can be synthesised 
and secreted by epithelial cells (Kawakastu et al., 1992; Latijnhouwers et al., 1997. 
The increased tenascin expression in adenomas suggests two important functions of 
tenascin: proliferation and anti-adhesion. Under normal conditions the steadily dividing 
cells of the lower parts of the crypts of the intestine are situated on a tenascin positive 
basement membrane. In adenomas there is increased proliferation and turnover of cells; 
therefore tenascin expression is expected to increase. A remarkable finding in our study 
was the thickening of and increased tenascin expression in the muscularis mucosae seen 
in adenomas in contact with the muscularis mucosae and in carcinomas invading  the 
muscularis mucosae. This suggests that tumour cells are stimulating tenascin synthesis 
by stromal cells. Lymph vessels which contained tumour cells, adjoining the muscularis 
mucosae, were surrounded by thin bands of tenascin (Fig.4) wheras around similar 
vessels deeper in the submucosa this tenascin pattern was absent in many cases; this 
suggests that after invasion of the muscularis mucosae, tenascin is no longer necessary. 
A similar process has been demonstrated in wound healing where tenascin is increased 
during the active process of wound healing and lost in old scars (Mackie et al., 1988).
  Two different patterns of tenascin expression were found in 
adenocarcinomas: the fibrillary expression pattern around glands and cysts of well-
differentiated tumours and the network-like expression pattern in poorly differentiated 
tumours, as has been described in human tumours (Broll et al., 1995; Gulubova 
& Vlaykoya, 2001). In human colon cancer tenascin is expressed more in well-
differentiated tumours than in poorly differentiated tumours (Sakai et al., 1993; 
Gulubova & Vlaykoya, 2001). Tenascin expression in canine tumours showed the same 
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tendency. The absence of tenascin in some regions of adenocarcinomas and carcinomas 
demonstrates that tenascin is not indispensable for invasion. The presence of tenascin 
in both adenomas and carcinomas in our study suggests that tenascin cannot be used as 
a stromal marker for malignancy as claimed in human mammary tumours (Howeedy et 
al., 1990).
  α-SMA expression in the normal gastric and intestinal mucosa has 
been described in cells around crypts (pericryptal myofibroblasts), pericytes and 
smooth muscle fibres of the muscularis mucosae and muscularis propria (Sappino et 
al., 1989; Skalli et al., 1989a). Our results in canine tissues showed the same reaction 
pattern. Theoretically myofibroblasts in gastrointestinal tumours can arise from 
phenotypic modulation of preexisting fibroblasts, pericytes and smooth muscle cells 
of the muscularis mucosae and muscularis propria. The strategy frequently applied to 
determine the origin of myofibroblasts is to examine the phenotype using cytoskeletal 
proteins α-SMA, vimentin, and desmin. It has been proposed that myofibroblasts in 
human breast carcinomas originate from preexisting fibroblasts and not from smooth 
muscle cells, because the cells expressed vimentin and not desmin (Schürch et al., 1984). 
In our study a persistent sheath of α-SMA positive cells was found, bordering epithelial 
cells in all adenomas regardless of their histological type. These cells did not express 
desmin except in areas near the muscularis mucosae. This is in contrast to findings in 
human colon adenomas, where α-SMA was only expressed in stromal cells of villous 
adenomas and not in tubular adenomas (Sappino et al., 1989). In carcinomas, stromal 
cells representing desmoplasia were positive for vimentin and α-SMA and negative for 
desmin. Desmin was only positive in areas near the muscularis mucosae. Based on these 
results we propose that myofibroblasts in the stroma of canine gastrointestinal tumours 
are most likely to originate from pre-existing fibroblasts and not smooth muscle cells 
except in tumour regions near the muscularis mucosae.
  The co-localization of tenascin and myofibroblasts can be explained by 
two possible different mechanisms. First, tenascin can act as a mediator in the epithelial 
mesenchymal interaction resulting in the stimulation of stromal cells to express α-SMA 
filaments as suggested in the process of human intestinal development (Beaulieu et al., 
1993). Second, the regulation of tenascin synthesis and transformation of fibroblasts 
to myofibroblasts is influenced by the same cytokines produced by the tumour cells. 
A variety of tumour cells secrete cytokines that confer a transformed phenotype of 
fibroblasts to myofibroblasts (Desmouliére et al., 1993, Rønnov-Jessen and Petersen, 
1993). Cytokines of particular interests are TGF-β and GM-CSF. When TGF-β and 
GM-CSF are administered subcutaneously in rats, they induce formation of granulation 
tissue in which α-SMA expressing myofibroblasts are present (Rubbia-Brandt et al., 
1991; Desmouliére et al., 1993). The assumption that cytokines produced by tumour 
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Abstract
Tenascin is an extracellular matrix glycoprotein that has been implicated in cell 
proliferation and adhesion by in vitro experiments. Its expression is known to be 
increased in canine and human gastrointestinal tumours. The aim of this study was to 
investigate the possible relationship between cell proliferation and tenascin expression 
in these tumours. In tissue sections of normal stomach, small intestine and colon, and 
gastrointestinal epithelial tumours, the monoclonal antibody Ki-67, which is directed 
against a proliferation-associated nuclear antigen, was used to identify proliferating 
cells. Serial sections were also stained for tenascin. Serial sections stained for tenascin 
and Ki-67 were compared to determine whether there is a correlation between tenascin 
expression and tumour cell proliferation. In the normal gastric mucosa, Ki-67 positive 
cells were confined to the neck region and in the normal small intestinal mucosa positive 
cells were confined to the lower parts of the crypts. In adenomas and carcinomas, the 
frequency of positive cells was increased at the edges of adenomas and invasive 
tumour margins of carcinomas and there was inter- and intra- tumoural heterogeneity. 
Carcinomas with lymphatic invasion showed a high Ki-67-index.  There was no relation 
between cell proliferation and tenascin expression in both normal tissues and tumours 
studied. The absence of a correlation between tenascin and Ki-67 expression suggests 
that the main function of tenascin in both normal tissues and tumours of the canine 
gastrointestinal tract is anti-adhesion rather than proliferation.  
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Introduction
Epithelial tumours are composed of two discrete interdependent compartments: the 
neoplastic epithelial cells and the reactive stroma. Identification of tumour properties 
that may help identify tumours that have malignant behaviour is one of the major aims 
in tumour research. The tumour properties can basically be divided into two: properties 
of the tumour cells and properties of the tumour stroma or extracellular matrix 
components. These properties are not totally independent.
  There is increasing evidence that proliferative activity measured by 
Ki-67 expression may be a useful measure of the malignancy potential for a variety 
of gut tumours (Yonemura et al 1990, Johnston et al 1989). It has been used to study 
proliferative activity of human tumour cells of different origin (Yonemura et al 1990, 
Porschen et al 1991, Kim et al 2001). Quantitative measures of cellular proliferation 
have been tested in several canine tumours as prognostic indicators (Pẽna et al 1998, 
Phillips et al 2000).  Ki-67 antibody is directed against a nuclear antigen that is only 
expressed in proliferating cells of G1, G2, S and M phases of cell cycle. 
  Tenascin is a large polymorphic glycoprotein of the extracellular matrix, 
expressed transiently during embryogenesis, wound healing and neoplasia (reviewed 
by Mukaratirwa and Nederbragt 2002). In vitro experiments have shown that tenascin 
promotes proliferation of tumour cells (Chiquet-Ehrismann et al 1986). In human 
breast carcinomas, tenascin expression was found to be associated with tumour cell 
proliferation (Jahkola et al 1998). Increased tenascin expression has been demonstrated 
in canine gastrointestinal adenomas and carcinomas with a regional variation between 
different areas of the same tumour (Mukaratirwa 2003). It would therefore be of 
great interest to study the regions of tumours with increased tenascin expression with 
proliferation markers to determine whether there is a correlation between tenascin 
expression and tumour cell proliferation as seen in vitro experiments.
  While tenascin is a key player in the development of small intestine 
mucosa during embryogenesis (Beaulieu et al 1993), its role in the regulation of adult 
intestinal functions such as proliferation, migration of enterocytes and specific tissue 
gene expression remains to be established. Studies on cell kinetics in relation to tenascin 
expression pattern in tumours are rare (Goussia et al 2000, Kim et al 2000)
  The objective of this study was to assess the proliferative activity of 
the tumour cells and determine whether there is a correlation between the proliferative 
activity of tumour cells and tenascin expression around the tumour cells. 
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Material and methods
Case Materials
Blocks of formalin-fixed, paraffin wax-embedded tissue from cases of normal 
canine stomach (n=10), small intestine (n=10) and large intestine (n=10), and 
epithelial tumours of the gastrointestinal tract (11 adenomas, 14 adenocarcinomas, 
5 undifferentiated carcinomas) from dogs were retrieved from the Department of 
Pathology, Utrecht University. Table 1 shows a summary of the number, types and sites 
of tumours examined. Haematoxylin and Eosin-stained slides were re-evaluated by 
two pathologists and tumours were classified according to World Health Organisation 
classification of tumours of the lower alimentary tract (Head 1976). 
Table 1. Summary of the number, type and site of canine gastrointestinal tumours studied
Tumour Stomach Small 
intestine
Colon Rectum Total
Adenoma
     Tubular
     Tubulovillous
    0
    0
   0
   0
  1
  2
  2
  6
 3
 8
Adenocarcinoma
      Mucinous
      Tubular
       Solid/ signet ring 
    3
    3
    0
   0
   3
   1
  2
  1
  1
  0
  0
  0
 5
 7
 2
Undifferentiated 
Carcinoma
    
3
   
2   
 
 0
 
 0
 
5
Total 
    
9
  
 6
  
7
  
8  30
Immunohistochemistry
To study whether tenascin expression correlates with tumour cell proliferation, tenascin 
expression in tumour stroma was compared with Ki-67 expression in tumour cells in 
serial sections. Serial sections of each case were stained for tenascin and Ki-67. Tenascin 
labelling was carried out as previously described (Mukaratirwa 2000) using a monoclonal 
antibody (Clone TN2; Dako, Glostrup, Denmark) and Ki-67 immunohistochemistry 
was performed using monoclonal antibody MIB-1 (Biogenex, CA, USA). After de-
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waxing through xylol and graded alcohols, the sections were heated in a pressure cooker 
at 120oC for 10 minutes. The slides were cooled at room temperature for 60 minutes. 
Endogenous peroxidase activity was blocked by immersing the sections in 3% H
2
O
2
 in 
methanol for 30 minutes. Non-specific binding of secondary antibody was blocked by 
incubating the slides with normal horse serum diluted 1 in 50 for 30 minutes. Sections 
were then incubated with primary mouse anti-human Ki-67 antibody diluted 1 in 200 
overnight at 4oC. Biotinylated horse anti-mouse secondary antibody was applied for 
30 minutes at room temperature. Bound antibody was visualized with avidin-biotin-
peroxidase complex (Vector, Burlingame, USA). The colour was developed by 3,3’-
diaminobenzidine. The slides were counter-stained with haematoxylin. Positive control 
slides consisted of sections from human lymph nodes with follicular hyperplasia. 
Negative control slides were prepared by omitting the primary antibody. 
Microscopic analysis
In sections immunolabelled for Ki-67, the cell nuclei were identified as positive or 
negative and counted using a 400x objective lens. A Ki-67 index was defined as the 
number of tumour cells immunolabelled divided by the total number of tumour cells 
counted x 100. A total number of 1000 nuclei were counted in at least four random 
fields. The sections were scored as weakly positive when less than 20% of the nuclei 
were positive, moderate when 20-50% of the nuclei were positive and as strong when 
greater than 50% of the nuclei were positive. Serial sections stained for Ki-67 and 
tenascin were compared to determine whether there was a high Ki-67 index in tumour 
regions expressing tenascin.
Results
Tenascin Expression 
Tenascin expression pattern in the normal gastrointestinal mucosa and epithelial 
tumours was as described previously (Mukaratirwa, 2003). Briefly tenascin expression 
was absent in the normal mucosa of the stomach, but expressed in the normal intestine 
with a gradual increase from the cryptal glands to the surface epithelium. Tenascin 
expression was increased in both adenomas and carcinomas. Two different patterns 
of tenascin expression were observed in carcinomas. In well-differentiated tumour 
regions, a fibrillary sub-glandular expression was present and in poorly differentiated 
tumour regions a diffuse network expression pattern was present. In areas of incomplete 
invasion of the muscularis mucosae, the muscularis mucosae was thickened and tenascin 
expression was increased in these areas.
60
- Tenascin and Cell Proliferation - 
61
- Chapter 4 -
Ki-67 expression
Normal mucosa
Ki-67 positive cells exhibited a clearly recognizable reaction, which was located in the 
nucleus. In the normal gastric mucosa, cells in the glandular neck region were positive 
for Ki-67 and cells at the surface of the mucosa and glands were negative. This is 
consistent with the fact that in the gastric mucosa, cells proliferate from the neck region 
to the surface mucosa and down to the gastric glands. Stromal cells of the lamina propria 
and submucosa were negative. In the normal small intestine and colon, epithelial cells 
of the crypts were positive with a gradual decrease to the top of villi or surface mucosa 
(Fig 1). Cells at the surface were negative. This is consistent with the fact that in the 
intestine, cells proliferate from the crypts to the top of the villi or surface mucosa.
Tumours
Of the 11 adenomas studied Ki-67 expression was increased compared to the normal 
mucosa (Fig 2). Three cases were weakly positive, four were moderate and four were 
strongly positive. There was no relation between Ki-67 expression and the histological 
type of the adenoma. Some well-differentiated areas of the tumour were completely 
negative. Of the 14 adenocarcinomas, four were weakly positive, four were moderate 
and six were strongly positive. All the undifferentiated carcinomas were strongly 
positive for Ki-67 (Fig 3a). Stromal cells were negative for Ki-67. There was no 
relationship between Ki-67 index and the depth of tumour invasion or differentiation 
Fig 1:  Section of normal colon mucosa immunolabelled for Ki-67. Cryptal cells are positive and cells at the 
surface are negative for Ki-67 (1b). Avidin-biotin peroxidase (ABC), haematoxylin counterstain. x 100
Fig 2: Colon adenoma immunolabelled for Ki-67. Increased number of moderately Ki-67 positive cells. 
ABC, haematoxylin counterstain. x 200
1 2
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Fig3: Serial sections of a colon undifferentiated carcinoma immunolabelled for Ki-67 (3a) and tenascin 
(3b). Increased number of Ki-67 positive cells in (3a) and absence of tenascin expression in (3b). ABC, 
haematoxylin counterstain. x 200
Fig 4: Serial sections of a colon adenocarcinoma immunolabelled for Ki-67 (4a) and tenascin (4b). 
Increased number of Ki-67 positive cells at the invasive tumour margins (4a) is not related with increased 
tenascin expression at the tumour margins (4b). ABC, haematoxylin counterstain.  x 100
of the tumour. Ki-67 expression was increased on the edges of adenomas and at the 
invasive tumour margins of carcinomas (Fig 4a).
Relation Between Tenascin and Ki-67 Expression
Normal tissue
There was no correlation between tenascin expression in the stroma and Ki-67 expression 
in epithelial cells in the normal gastrointestinal mucosa. In the gastric mucosa there 
was no tenascin immunoreactivity, but Ki-67 was consistently expressed in cells of the 
glandular neck region. In the small intestine and colon tenascin was expressed with a 
decreasing gradient from crypts to surface epithelium, but Ki-67 was expressed in a 
3a 3b
4a 4b
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decreasing gradient from crypts to surface mucosa (Fig 1).
Tumours
In 8/11 adenomas there was no relation between tenascin and Ki-67 expression. In 2/11 
adenomas the intensity of tenascin expression was increased in tumour regions with 
high Ki-67 expression. In adenocarcinomas and undifferentiated carcinomas there was 
no relation between tenascin and Ki-67 expression (Fig 3a, 3b and Fig 4a, 4b), except 
in three cases (21%). Tenascin expression was not increased at invasive tumour margins 
where Ki-67 index was high (Fig 4a, 4b).
Discussions
Previous studies on cell kinetic parameters in human gastrointestinal tumours have 
shown that high proliferative activities measured by Ki-67 are associated with a poor 
prognosis (Johnston et al 1989, Yonemura et al 1990, Porschen et al 1991). In this study 
the pattern of Ki-67 expression in the normal gastrointestinal mucosa and tumours is 
in line with the reported pattern in humans (Johnston et al 1989). In adenomas and 
carcinomas, proliferating cells as identified by Ki-67 labelling were not uniformly 
distributed throughout the section and this was also observed in tenascin expression. 
Intra-tumoural heterogeneity of Ki-67 expression has also been demonstrated in human 
colon carcinomas (Johnston et al 1989). This phenomenon can be explained by the 
different tumour cell subpopulations within the carcinomas, and this is reflected by the 
differences in histological differentiation (Jass et al 1986), DNA content (Hiddemann et 
al 1986) and sensitivity to cytotoxic drugs (Kimball and Brattain 1980).
  In vitro studies have shown that tenascin plays a role in foetal and 
tumour cell proliferation (Chiquet-Ehrismann et al 1986). In our study, there was no 
relation between tenascin expression and cell proliferation in the normal gastrointestinal 
mucosa. While cells around the neck zone of the gastric mucosa expressed Ki-67, 
tenascin was not expressed at all. In the normal small intestine and colon Ki-67 positive 
cells were situated at the cryptal zone, while tenascin was expressed mainly at the 
mucosal surface. Our results suggest that the main function of tenascin in the normal 
gastrointestinal mucosa is cell shedding rather than proliferation.
In adenomas and carcinomas there was no clear correlation between tenascin expression 
and cell proliferation, except in three adenocarcinomas. These findings are in contrast 
with the findings in human intra-ductal carcinomas where peri-ductal tenascin 
expression was associated with increased Ki-67 expression (Jahkola et al 1998). The 
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absence of a clear correlation between tenascin expression and proliferation in our study 
might be due to the presence of different subpopulations of tumour cells within the same 
tumour as these might have different paracrine influence on the stromal components. 
Another more likely reason for the absence of correlation might be that isoforms of 
tenascin in gastrointestinal tract have different functional properties. The functional 
properties reported for tenascin are numerous and in some instances contradictory, 
largely depending on cell type and experimental conditions (Bélanger and Beaulieu et 
al 2000). In vitro studies with several gastrointestinal cell lines are required to assess the 
effects of different isoforms of tenascin on cell adhesion, proliferation, differentiation 
and migration.
  In conclusion, our study demonstrates that gastrointestinal carcinomas 
exhibit a wide variability in their proliferation rate with inter- and intra-tumoural 
differences, and that tenascin expression is not correlated to cell proliferation in tumours 
and normal mucosa.
                                  
References
BEAULIEU, J.F., JUTRAS, S., KUSAKABE, M. & PERREAULT, N. (1993) Expression of tenascin in the 
developing small intestine. Biochemical and Biophysical Research Communications 192, 1086-1092
BÉLANGER, I. & BEAULIEU J.F. (2000) Tenascin in the developing and adult human intestine. Histology 
and Histopathology 15, 577-585
CHIQUET-EHRISMANN, R., MACKIE, E.J., PEARSON, C.A. & SAKAKURA, T. (1986) Tenascin: an 
extracellular matrix protein involved in tissue interaction during fetal development and oncogenesis. Cell 
47, 131-139
HEAD, K.W. (1976) Tumours of the lower alimentary tract. Bulletin of the World Health Organization 53, 
167-186
GOUSSIA, A.C., IOACHIM, E.E., PESCHOS, D., ASSIMAKOPOULOS D.A., SKEVAS, A. & 
AGNANTIS, N.J. (2000) Expression of the extracellular matrix protein tenascin in laryngeal epithelial 
lesions: correlation with fibronectin, CD44, cathepsin D and proliferation indices. Virchows Archiv 436, 
579-584.
HIDDEMANN, W., VON BASSWITZ, D.B., KLEINEMEIER, H., SCHULTE-BROCHTERBECK, E., 
HAUSS, J. & LINGERMANN, B. (1986) DNA stemline heterogeneity in colorectal cancer. Cancer 58, 
258-263
JAHKOLA, T., TOIVONEN, T., NORDLING, S., VON SMITTEN, K. & VIRTANEN, I. (1998) 
Expression of tenacsin-C in intraductal carcinoma of human breast: relation to invasion. European Journal 
of Cancer 34, 1687-1692
64
- Tenascin and Cell Proliferation - 
CHAPTER
65
JASS, J.R., ATKIN, W.S., CUZICK, J., BUSSEY, H.J.R., MORSON, B.C. & NORTHOVER, J.M.A. 
(1986) The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. 
Histopathology 10, 437-459
JOHNSTON, P.G., O’BRIEN, M.J., DERVAN, P.A. & CARNEY, D.N. (1989) Immunohistochemical 
analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Human 
Pathology 20, 696-700
KIM, C.H., BAK, K.H., KIM, Y.S., KIM, J.M., KO, Y., OH S.J., KIM, K.M. & HONG E.K. (2000) 
Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surgical 
Neurology 54, 235-240
KIMBALL, P.M. & BRATTAIN, M.G. (1980) Isolation of a cellular subpopulation from a human colonic 
carcinoma cell line. Cancer Research 40, 1574-1579 
MUKARATIRWA S., de WITTE, E., van EDEREN, A.M, NEDERBRAGHT, H. (2003), 
Tenascin expression  in relation to stromal tumour cells in canine gastrointestinal 
epithelial tumours, Journal of Comparative Pathology 129 (2003) 137-146. 
MUKARATIRWA, S. & NEDERBRAGT, H. (2002) Tenascin and proteoglycans: the role of tenascin and 
glycoproteins in canine tumours. Research in Veterinary Science, 73, 1-8
PEÑA, L.L., NEITO, A.I., PÉREZ-ALENZA, D., CUESTA, P. & CASTAÑO, M. (1998) 
Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical 
and pathologic variables. Journal of Veterinary Diagnostic Investigation 10, 237-246
PHILLIPS, B.S., KASS, P.H., NAYDAN, D.K., WINTHROP, M.D., GRIFFEY, S.M. & MADEWELL 
B.R. (2000) Apoptotic and proliferation indexes in canine lymphoma. Journal of Veterinary Diagnostic 
Investigation 12, 111-117.
PORSCHEN, R., KRIEGEL, A., LANGEN, C., CLASSEN, S., HILSE, M., LOHE, B., HENGELS, K.J. 
& BORCHARD, F. (1991) Assessment of proliferative activity in carcinomas of human alimentary tract by 
Ki-67 immunostaining. International Journal of Cancer 47, 686-691 
YONEMURA, Y., OOYAMA, S., SUGIYAMA, K., NIMOMIYA, I., KAMATA, T., YAMAGUCHI, A., 
MASTUMOTO, H. & MIYAZAKI, I. (1990) Growth fractions in gastric carcinomas determined with 
monoclonal antibody Ki-67. Cancer 65, 1130-1134
        
64
- Tenascin and Cell Proliferation - 
CHAPTER
65
5
Versican and Hyaluronan Expression in Canine Colonic 
Adenomas and Carcinomas: Relation to Malignancy and 
Depth of Tumour Invasion
S. Mukaratirwa1,2, A. M. van Ederen1, E.Gruys1, H. Nederbragt1 
1Department of Pathobiology, Division of Pathology, Utrecht University
2Department of Paraclinical Studies, Faculty  of Veterinary Science, University of 
Zimbabwe
Accepted in Journal of Comparative Pathology
66
- Versican and Hyaluronan in Canine Colonic Tumours -
67
- Chapter 5 -
Abstract 
Altered levels of production and structural changes in glycosaminoglycans and 
proteoglycans have been reported in many neoplastic tissues. Versican and hyaluronan 
are extracellular matrix components that are frequently increased in tumours and 
promote tumour progression through various mechanisms. We analysed the histological 
distribution of chondroitin sulphate, versican and hyaluronan in normal canine 
colonic wall (n=10) and colonic lymph nodes (n=10), and colonic adenomas (n=22), 
adenocarcinomas (n=28), undifferentiated carcinomas (n=7) and colonic lymph node 
metastases (n=8), using antibodies against chondroitin sulphate and versican, and a 
specific biotinylated probe for hyaluronan. The epithelial cells of the colonic mucosa 
were negative for chondroitin sulphate versican and hyaluronan, whereas the stromal 
tissue and lamina propria were moderately positive for chondroitin sulphate and 
hyaluronan, and weakly positive for versican. Versican expression was increased in 
the peritumoral stroma of adenocarcinomas and reduced in adenomas. A significant 
correlation was observed between grade of the tumour and versican intensity. In 13 
adenocarcinomas and undifferentiated carcinomas with invasion into all layers of the 
colorectum, the intensity of stromal versican expression was significantly related to the 
depth of invasion; the intensity was increased in the stroma of tumour islands in deep 
layers of the colonic wall. Unlike versican, hyaluronan expression was increased in the 
stromal tissue of both adenomas and carcinomas. However, there was no correlation 
between stromal hyaluronan intensity and grade of the tumour or depth of tumour 
invasion. Hyaluronan was also expressed in the membrane and in the cytoplasm of 
tumour cells in 3/22 (14%) adenomas and 18/28 (64%) adenocarcinomas and 2/7 (29%) 
undifferentiated carcinomas. These results suggest that altered levels of both versican 
and hyaluronan in canine colonic tumours affect tumour progression.
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Introduction
A marked production of stromal (desmoplastic) tissue is a well-recognized phenomenon 
in a variety of tumours including canine colonic tumours. Changes in the newly formed 
stromal tissue may influence and facilitate tumour cell proliferation, invasion and 
metastasis.
  Proteoglycans are macromolecules that contain glycosaminoglycans 
covalently linked to a core protein. They are intrinsic constituents of the newly formed 
stromal tissue and have been implicated in a number of biological processes necessary 
for tumour progression including cell adhesion (Ruoslahti, 1988), and cell growth (San 
Antanio et al., 1987). Chondroitin sulphates proteoglycans (CS-PGs) are components of 
both cell membranes and extracellular matrix.  The composition of CS-PGs in various 
neoplastic tissues is in much higher concentration than in normal tissues (Iozzo and 
Wright, 1982; Alini and Losa, 1991; Ricciardelli et al., 1997; Hinrichs et al., 1999). In 
human colon carcinomas, increased levels and altered structure of CS-PGs have been 
reported (Adany et al, 1990). The proteoglycan responsible for the accumulation of 
CS-PGs in the peritumoral stroma is not known. Versican, a large CS-PG, has been 
proposed to be responsible for the association of CS-PGs with breast (Ricciardelli et al., 
2002) and prostatic (Ricciardelli et al., 1998) tumours. Versican is synthesized mainly 
by stromal cells, and has anti-adhesive properties involved in cell motility (Yamagata et 
al., 1989; Yamagata et al., 1993).
  Hyaluronan is a high molecular weight linear glycosaminoglycan 
composed of repeating disaccharides of glucouronic acid and N-acetylglucosamine. 
Newly synthesized hyaluronan is extruded directly into cell surface; it is either 
retained there by sustained attachment to the hyaluronate synthase or by interactions 
with receptors, or it is released into pericellular and extracellular matrices (Fraser et 
al., 1997). Hyaluronan is involved in various cell functions such as adhesion, motility 
and differentiation (Laurent and Fraser., 1992; Toole, 1989). Many human epithelial 
tumours are surrounded by a connective tissue matrix (stroma) enriched in hyaluronan 
(Knudson, 1996). In human breast (Auvinen et al., 2000), ovarian (Antilla et al., 
2000), and colorectal (Ropponen et al., 1998) carcinomas, a high level of hyaluronan 
association with cancer cells themselves or with tumour stroma is a reliable prognostic 
indicator of patient morbidity.
  The primary sequence of versican shows that the amino-terminal 
domain contains sequence homology with known hyaluronan-binding proteins 
(Zimmermann and Ruoslahti, 1989). LeBaron et al., (1992) showed that versican 
specifically binds to hyaluronan with a high affinity, and the amino-terminal domain of 
versican mediates this binding. The binding of versican to hyaluronan therefore might 
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have a biological significance in neoplastic conditions, where both these molecules have 
an altered expression.
  Despite the extensive evidence of increased versican and hyaluronan 
expression in human colonic tumours, and general ability of these two extracellular 
molecules to promote tumour progression, no studies on the expression of these 
molecules in canine colorectal tumours have been reported. 
 The aim of this study was to determine (1) the expression of chondroitin 
sulphate, versican and hyaluronan in the peritumoral stroma and epithelial cells of normal 
canine colon and colonic epithelial tumours, (2) the relation between the expression of 
versican and hyaluronan in these tumours, and (3) the relation between the expression 
of these molecules with depth of tumour invasion, and lymph node metastasis.
Materials and methods
Case materials
From the archives (computerized data) of the Division of Veterinary Pathology, Utrecht 
of University, and the Department of Paraclinical of Veterinary Studies, University of 
Zimbabwe, cases of canine colonic tumours revealing full-thickness sections of the 
colorectal wall were selected. The cases consisted of colonic adenomas (n=22, of which 
7 were classified as papillary, 6 tubular and 9 papillotubular), adenocarcinomas (n=28, 
of which 6 were classified as papillary, 17 tubular and 5 mucinous adenocarcinomas) 
and undifferentiated carcinomas (n=7). Eight cases of carcinomas (5 adenocarcinomas 
and 3 undifferentiated carcinomas had colonic lymph node metastases). In addition, 
full thickness samples of normal colon and normal colonic lymph nodes were obtained 
fro 10 other dogs. Haematoxylin and eosin-stained sections were made to confirm the 
original diagnoses. The tumours were classified according to the WHO classification 
of tumours of the lower alimentary tract (Head, 1976). The stage of the tumour spread, 
i.e. depth of tumour invasion into the colonic wall (mucosal, submucosal, muscular, 
serosal) was registered in all carcinomas. The malignancy of the tumour was graded 1-6 
as adenoma, carcinoma with muscularis mucosae invasion, carcinoma with submucosa 
invasion, carcinoma musucularis propria invasion, carcinoma with serosa invasion, and 
carcinoma with metastases in local colonic lymph nodes.  
Antibodies and biotinylated hyaluronan probe
The antibodies used in this study are: (1) anti-mouse monoclonal antibody CS-56 
(clone CS-56, Sigma Chemicals Company, St Louis, MO, USA), which recognizes 
native epitopes in intact chondroitin sulphate proteoglycans (Avnur and Geiger, 
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1984) and represent a mixture of chondroitin sulphate proteoglycans (2) anti-human 
monoclonal large chondroitin sulphate 2B1 (Seikagaku Company, Kogyo, Tokyo, 
Japan), which recognize versican (Sobue et al., 1989); (3) anti-human monoclonal 12C5 
(Developmental Studies Hybridoma Bank, Iowa City, IA, USA), raised against versican 
isolated from brain (Asher et al, 1991). A biotinylated hyaluronan-binding complex 
(bHABC) was obtained from Seikagaku Company. 
Immunohistochemical labelling
Representative sections of each tumour and normal colon tissues were selected for 
immunohistochemical and histochemical analysis of versican and chondroitin sulphate. 
Unstained sections of the tissues were de-waxed and stained using the avidin-biotin 
complex method (Hsu et al., 1981). In each case, 4-μm sections of formalin-fixed, 
paraffin wax-embedded tissues were mounted on poly-L-lysine coated slides. The slides 
were de-waxed through xylol and graded alcohols. Sections to be labelled for versican 
were incubated with chondroitinase ABC (Sigma) at a concentration of 2 units/ml in 
0.25M Tris/HCl buffer (pH 8) for 1 hour. For versican retrieval, antigen was unmasked 
by treatment for 10 minutes at 37oC with trypsin 0.1% in phosphate buffered saline 
(PBS) containing CaCl
2 
0.1% (0.01M, pH 7.4) at a final pH of 7.8. No antigen retrieval 
was performed for chondroitin sulphate. Endogenous peroxidase activity was blocked 
by H
2
O
2
 0.3% in PBS for 30 minutes. After incubation with normal horse serum diluted 
1 in 10 for 30 minutes to block background staining, the sections were treated with 
primary antibodies CS-56 (1 in 100, 2B1 (1 in 1000), 12CS (1 in 500) at 4oC overnight. 
After incubation with horse anti-mouse biotin and avidin-biotin peroxidase complex 
(Vector, Burlingame, CA, USA), the colour was developed in 3-3’-diaminobenzidine 
and 0.02% H
2
O
2
 in Tris buffer pH 7.8. The sections were counter-stained with 10% 
Mayer’s haematoxylin. Rat and human tissues were used as positive controls and the 
primary antibodies were replaced with normal mouse serum as negative controls. For 
chondroitin sulphate immunolabelling, tissue sections treated with chondroitinase ABC 
(Sigma) were also used as negative controls.
Histochemical labelling of hyaluronan
The slides were de-waxed through xylol and graded alcohols. Endogenous peroxidase 
was blocked with H
2
O
2
 1% for 5 min and non-specific binding was blocked with 
bovine serum albumin (BSA) 1% in PBS for 30 min. The sections were incubated in 
botinylated hyaluronan binding complex (bHABC) (2.5 µg/ml, diluted in BSA 1%) 
overnight at 4°C. After incubation with horse anti-mouse biotin and avidin-biotin 
peroxidase complex (Vector), the colour was developed in 3-3’-diaminobenzidine and 
H
2
O
2
 0.02% in Tris buffer pH 7.8. The sections were counter-stained with 10% Mayer’s 
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haematoxylin. The specificity of the staining was controlled by digesting some sections 
with Streptomyces hyaluronidase (Seikagaku) in the presence of protease inhibitors 
before staining.
Evaluation of versican, and hyaluronan and statistical analysis
The intensity of stromal versican and hyaluronan varied within each section, but the 
strongest and the negative reaction could always be identified and were comparable 
between different sections. The levels of stromal versican and hyaluronan expression 
in the tumours was graded semi-quantitatively as negative (-), weak (+), moderate (++) 
or strong), and recorded 0-3, respectively. The statistics were computed using SAS 
for Windows Package (Version 6. SAS Institute Inc., Raleigh, North Carolina, USA). 
To examine the correlation between versican or hyaluronan intensity and grade of the 
tumour, the Spearman rank-correlation test was used. The relationship between versican 
intensity and depth of tumour invasion was tested using chi-square analysis. A P less 
than 0.05 was defined as statistically signifi
Results
Twenty-two colonic adenomas, 28 adenocarcionmas, and 7 undifferentiated carcinomas 
were re-examined and graded for malignancy (Table 1). Eight carcinomas had invasion 
up to and including the muscularis mucosae, 8 up to and including the submucosa, 6 up 
to and including the muscularis propria, and 8 up to and including the serosa and 8 had 
colonic lymph node metastases.
Chondroitin sulphate expression in normal colon and tumours
In the normal colon, chondroitin sulphate was expressed in the stroma surrounding 
the crypts, and was associated with the basement membrane. Epithelial cells of the 
normal colonic mucosa were negative for chondroitin sulphate. There was a weak 
immunolabelling of the submucosal side of the lamina propria, and no immunolabelling 
in the submucosa and serosa, and a weak immunolabelling in the muscle layers. 
  In adenomas, there was no basement immunolabelling of chondroitin 
sulphate except around cystic structures, and there was no labelling in tumour cells. 
There was a moderate immunolabelling in the stroma of 64% (12/20) of the adenomas. 
At points where tumour cells were close or in contact with muscularis mucosae, there 
was thickening and increased intensity of chondroitin sulphate immunolabelling. In 
adenocarcinomas and carcinomas, there was little chondroitin sulphate labelling in 
the tumour stroma when the tumour was in the mucosa. There was increased stromal 
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chondroitin sulphate immunolabelling in the muscularis mucosa at points of invasion. 
In the submucosa, muscularis propria and serosa, the intensity of peritumoural 
chondroitin sulphate labelling was increased. However, there was no relation between 
the depth of invasion and intensity of stromal chondroitin sulphate immunolabelling
  
Versican expression in normal colon and tumours
In the normal colon, there was no immunolabelling of the epithelial cells. There was, 
however, a weak immunolabelling in the stromal tissue around cryptal cells near the 
muscularis mucosa (Fig. 1). The submucosa was negative, except the media of large 
blood vessels. In the muscular layers of the colon (muscularis mucosae and muscularis 
propria), there was a strong immunolabelling in the septa surrounding the muscles 
(Fig. 1).           
   In adenomas, there was no stromal versican immunolabelling 
(Fig. 2), whereas strong labelling was observed in the stromal tissue associated with 
adenocarcinomas (Fig. 3). According to Spearman rank-correlation test, there was 
a significant correlation between tumour grade and versican intensity (coefficient = 
0.88, n=57, P< 0.0001) (Table 1). The intensity of versican immunolabelling in the 
peritumoural stroma was also related to the depth of invasion in carcinomas (χ2=0.0001) 
(Table 2). When the tumour was present in the mucosa, there was almost negligible 
versican labelling (Fig. 3a). When invasion was present in the submucosa and muscularis 
mucosa, there was a moderate to strong labelling, whereas, when invasion was present 
in the serosa, intense versican labelling was present (Fig. 3b, 3c). There were no 
Fig. 2. Papillary adenoma immunolabelled for 
versican. No stromal and tumour cell reactivity. 
ABC, haematoxylin counter-stain. x 200
Fig. 1. Normal colon immunolabelled for versican. 
Weak immunoreactivity in the stromal tissue around 
cryptal cells near the muscularis mucosa, and strong 
immunoreactivity in the septa surrounding the 
muscles in the muscularis mucosa.  Avidin-biotin 
peroxidase complex (ABC), haematoxylin counter-
stain. x 40 (refer to colour picture page 156)
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Fig. 3. Tubular adenocarcinoma immunolabelled for versican in different parts of the colonic wall; a) 
mucosa, no stromal immunoreactivity (refer to colour picture page 156), x 100, b) submucosa, moderate 
stromal immunoreactivity, x 200, c) serosa, strong immunoreactivity, x 200. ABC, haematoxylin counter-
stain. 
Fig. 4. Undifferentiated carcinoma immunolabelled for versican. Invasion in the serosa, strong diffuse net-
like immunoreactivity. ABC, haematoxylin counter-stain. x 100
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instances where normal epithelial cells or tumour cells were labelled for versican in 
both adenomas and adenocarcinomas. In undifferentiated carcinomas, a diffuse net-like 
expression was present around tumour cells (Fig. 4), and the immunolabelling varied 
with depth of invasion as in adenocarcinomas.
Hyaluronan expression in normal colon and tumours
In the normal colonic mucosa, there was no labelling in epithelial cells. There was 
a moderate labelling in the lamina propria and stromal tissue surrounding epithelial 
cells (Fig. 5). The muscularis mucosa was weakly positive, while the submucosa was 
negative. In the muscular layers, hyaluronan was localized in septa surrounding muscles 
and blood vessels, but the muscle itself was weakly positive.
  Hyaluronan was expressed in the stromal tissue of 86% (19/22) of 
the adenomas (3 weak, 10 moderate and 6 strong) (Fig. 6), and in epithelial tumour 
cells in 14% (3/22) of the adenomas. The intensity of stromal hyaluronan labelling 
was not associated with the type of adenoma (papillary, tubular or tubulopapillary). In 
adenocarcinomas, hyaluronan was localized in the stroma of 27/28 (96%) of the tumours 
(4 weak, 9 moderate, 14 strong) (Fig. 7). The staining intensity varied greatly within 
Fig. 5. Normal colon mucosa immunolabelled for 
hyaluronan. Moderate reactivity in the lamina propria 
and stromal tissue surrounding epithelial cells, and 
weak reactivity in the muscularis mucosae.   ABC, 
haematoxylin counter-stain. x 40
Fig. 6. Tubular adenoma labelled for hyaluronan. 
Moderate reactivity in the stromal tissue.  ABC, 
haematoxylin counter-stain. x 200
Fig. 7. Tubular adenocarcinoma labelled for hyaluronan. 
Invasion into the serosa, strong stromal reactivity. ABC, 
haematoxylin counter-stain. x 200
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the same tumour and was not related to the grade of the tumour (Table 1) or the depth 
of invasion (Table 2). However, moderate and strong labelling was often associated 
with poorly differentiated regions.  Sixty-four percent (18/28) of adenocarcinomas were 
positive for epithelial hyaluronan with variable intensity and percentage of positive 
cells. The hyaluronan was detected on the cell membrane and/cytoplasm of the tumour 
cells (Fig. 8). The intensity and number of tumour cells expressing hyaluronan did not 
increase with the depth of invasion. In undifferentiated carcinomas, the same pattern of 
hyaluronan expression was found as in adenocarcinomas. 
Chondrotin sulphate, versican and hyaluronan expression in local colonic lymph node 
metastases
In the normal lymph node without tumour metastases, there was moderate 
immunoreactivity of chondroitin sulphate and weak labelling of versican and 
hyaluronan in the capsule. A total of 8 cases with colonic lymph-nodes metastases 
were examined. In lymph nodes with tumour metastases, there was intense chondroitin 
sulphate immunolabelling in the peritumoral stroma, and there was a strong chondroitin 
sulphate and versican immunolabelling in the peritumoural stroma. The intensity of 
versican labelling in the peritumoural stroma was stronger in the colonic lymph node 
Fig. 8. Tubular adenocarcinoma labelled for hyaluronan. 
Invasion into the serosa, membranous and cytoplasmic 
reactivity of tumour cells. ABC, haematoxylin counter-
stain. x 400 (refer to colour picture page 156)
Fig. 9. Tubular adenocarcinoma metastases in the 
colonic lymph node labelled for versican. Strong 
immunoreactivity around metastatic foci. ABC, 
haematoxylin counter-stain. x 200
Fig. 10. Undifferentiated carcinoma metastases in the 
colonic lymph node immunolabelled for hyaluronan. 
Strong stromal reactivity around metastatic foci. ABC, 
haematoxylin counter-stain. x 100
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metastases than in the primary tumour of the colon (Fig. 9). Hyaluronan was expressed 
in the peritumoural stroma of all the metastases in the lymph node (6 strong and 2 
moderate) (Fig.10), and was not expressed in tumour cells in any of the metastases.
Discussion
The present study describes for the first time the distribution chondroitin sulphate, 
versican and hyaluronan in normal canine colon, and canine colonic adenomas and 
carcinomas. It shows that the tumour stroma is enriched in chondroitin sulphate, versican 
and hyaluronan compared to the supporting stroma of the normal colonic mucosa. This 
peritumoural deposition of chondroitin sulphate, versican and hyaluronan, indicates 
that there is stimulation of stromal cells by tumour cells to synthesize and deposit these 
molecules into the extracellular matrix. The exact mechanisms of how these molecules 
are increased in tumours and how these molecules in turn modulate tumour progression 
are still not clear. The modulation of stromal cell activity by tumour cells can occur in 
three ways: cytokines secreted by tumour cells, extracellular matrix proteins secreted by 
tumour cells, and direct cell-cell contact. In vitro studies have shown that culture media 
conditioned by human breast (Riccciardelli et al., 2002) and human prostate (Sakko et 
al., 2001) cancer cells stimulate versican production by fibroblasts. The cytokines or 
soluble factors inducing versican and hyaluronan secretion by fibroblasts remain to be 
determined. In addition, the increased concentration of versican and hyaluronan can 
result from decreased degradation of the extracellular matrix.
  There was increased chondroitin sulphate expression in both adenomas 
and carcinomas compared to normal tissue. These observations are in agreement with 
the reported chondroitin sulphate expression in human colonic tumours (Yamori et 
al., 1988). In our study, there was no difference in chondroitin sulphate expression in 
adenomas, carcinomas and metastatic foci in lymph nodes. In human colon carcinomas, 
chondroitin sulphate deposits were found to be higher in metastatic foci in the liver and 
lymph nodes than in the primary tumours (Yamori et al., 1988). 
However, a high level of chondroitin sulphate in primary human colorectal tumours is 
not predictive of tumour recurrence (Yamori et al., 1988).
  Immunostaining of colonic tumour sections demonstrated negligible 
deposition of versican in the stroma of adenomas, whereas prominent immunolabelling 
of versican was present in the peritumoural stroma of carcinomas, suggesting that 
versican expression can be used to differentiate adenomas from carcinomas. These 
observations are in line with the reported versican immunoreactivity in human 
melanocytic (Touab et al., 2002) and breast (Nara et al., 1997; Ricciardelli et al., 2002) 
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tumours. In both adenomas and carcinomas, there were no instances where cancer 
cells were immunolabelled for versican, confirming observations in human prostate 
(Ricciardelli et al., 1998) and breast (Nara et al., 1997; Ricciardelli et al., 2002) 
tumours, that versican is mainly a product of stromal cells. Most of the stromal cells in 
canine colon tumours have been proved to be myofibroblasts and also responsible for 
secretion of tenascin (Mukaratirwa et al., in press), an anti-adhesion molecule. 
  A significant correlation (P=0.0001) was observed between malignancy 
and versican intensity. Moreover, there was also a significant relation (P=0.0001) 
between location or depth of invasion and versican intensity. The significant correlation 
between intensity of stromal versican immunoreactivity and depth of invasion suggests 
that versican supports tumour cell progression, migration and invasion. Aggressive 
cancer cells, which are able to invade deeper into the colonic wall, are capable of 
stimulating versican production by fibroblasts, which in turn may be involved in tumour 
progression. This trend was also observed in colonic lymph node metastases where the 
versican intensity was even higher than in the corresponding primary tumours. In this 
connection, it is known that versican regulates cell adhesion, proliferation, migration, 
and extracellular matrix assembly (Wight, 2002).
  Hyaluronan expression in the stromal tissue was increased in both 
adenomas and adenocarcinomas, but there was no relation of hyaluronan level 
of expression with the depth of invasion, suggesting that relative level of stromal 
hyaluronan expression cannot be used as a marker of malignancy. The intensity and 
number of tumour cells positive for hyaluronan were not related to the depth of invasion. 
This is in contrast to human breast (Auvinen et al., 2000), gastric (Setälä et al., 1999) 
and colorectal (Ropponen et al., 1998) cancer, where tumour cell-associated hyaluronan 
expression is related to local and nodal spread and an unfavourable prognosis. The 
increased hyaluronan expression in the stroma of both adenomas and carcinomas may 
give the neoplastic cells a growth advantage, as hyaluronan creates highly hydrated 
matrices, which enhance cell locomotion and proliferation (Knudson and Knudson, 
1990; Yang et al., 1993), stimulates angiogenesis (Rooney et al., 1995), and block 
lymphocyte-mediated cytolysis (McBride and Bard, 1979). 
  The co-localization of versican and hyaluronan in the peritumoural 
stroma of adenocarcinomas suggests that these molecules function together during 
tumour progression. In vitro studies have shown that one function of versican/
hyaluronan-rich pericellular matrix is to destabilize cellular attachment to the substrate 
during proliferation and migration (Evanko et al., 1999). Further studies should be 
done on the interaction between versican and hyaluronan, and how they are involved in 
tumour cell proliferation and invasion. 
  In conclusion, our results confirm that CS-PGs, versican and hyaluronan 
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are important components of the extracellular matrix of colonic tumours. The increase 
of all these extracellular matrix molecules may reflect the general activation of the 
stroma by the tumour cells and may be important for  tumour cell proliferation, invasion 
and metastasis. 
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Abstract
Canine transmissible venereal tumour (CTVT) is the only known naturally occurring 
tumour that can be transplanted as an allograft across major histocompatibility (MHC) 
barriers within the same species, and even to other members of the canine family, 
such as foxes, coyotes and wolves. The progression of this tumour is unique in that, 
it follows a predictable growth pattern. In natural and experimental cases, the growth 
pattern includes progressive growth phase, static phase and regression phase, and this 
is followed by transplantation immunity in immunocompetent adults, while metastasis 
occurs in puppies and immunosuppressed dogs. Because of the uniqueness of CTVT 
transmission and progression, experimental investigations of various aspects of the 
biology of CTVT have been used to provide clues to the immunobiology of both animal 
and human tumours. This review examines the current state of knowledge of the aspects 
of the cytogenetic origin, immunopheynotype, immunobiology and immunotherapy of 
CTVT.
Key words
canine / transmissible venereal tumour / immunophenotype / immunobiology / 
cytogenetic origin 
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Introduction
Canine transmissible venereal tumour (CTVT), also known as canine transmissible 
sarcoma, is a naturally occurring contagious round cell neoplasm of dogs located 
mainly on the external genitalia of both sexes. It is transplanted during coitus with intact 
viable cells across MHC barriers, and even to other members of the canine family, such 
as foxes, coyotes, and jackals [37]. Laboratory transplantation of CTVT from one dog to 
another using viable cells is also possible [91]. Metastasis of CTVT is uncommon, only 
occurring in puppies and immunocompromised dogs. Most of the reported metastasis 
cases actually are mechanical extensions of growth or transplantation to skin, cervix, 
uterus, and fallopian tubes from the tumour at the external genitalia.  However, distant 
metastasis to the inguinal lymph nodes and brain [3, 30, 74], adenohypophysis [53], and 
liver [89] has been reported.
   The uniqueness of CTVT lies in the fact that this is the only proven 
example of a naturally occurring tumour that is transmitted as an allograft by cell 
transplantation, and the tumour becomes autonomous from the original host. In other 
words, the tumour behaves like a parasite. This kind of tumour developed only in 
the dog, probably because during coitus there is extensive abrasions and bleeding of 
the penile mucosa and vagina, making transplantation of the tumour easy. Because 
CTVT can be easily transplanted as an allograft across MHC barriers, investigations 
of various aspects of tumour biology (cytogenetics, immunophenotype, immunology, 
immunotherapy, radiotherapy and chemotherapy) have been done to provide clues to 
similar phenomenon that occur in other animal and human tumours. Thus, CTVT has 
been studied extensively as a model of both animal and human tumours.
  A very interesting aspect that has attracted attention of CTVT is the 
role of the host’s immune response during the progressive and regressive stages of the 
tumour. Spontaneous and experimentally transplanted CTVT shows an initial stage of 
rapid tumour growth followed by a regressive stage that often complete in adult animals. 
Several reasons supported by both in vitro and in vivo studies have been proposed as to 
how CTVT initially evade the immune system and later succumb. 
  A review limited to the epidemiology and clinico-pathological features 
has already been published [23]. The aim of this paper is to review the current knowledge 
of the cytogenetic origin, immunophenotype, immunobiology and immunotherapy 
of CTVT, and to discuss how these tumour characteristics are involved in the unique 
behaviour of this tumour.
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Cytogenetic origin
The normal diploid number of chromosomes in the somatic cell of the dog (Canis 
familiaris) is 78, and 76 of these, the autosomal chromosomes are acrocentric, while 
two, the sex chromosomes are metacentric [66]. Cytogenetic studies on spontaneous and 
experimentally transplanted CTVT have been done by several researchers in different 
geographical areas of the world, and these studies have demonstrated that tumours from 
different geographical regions (France, Jamaica, Japan, Kenya, Nigeria, Uganda, USSR, 
and USA) have a similar karyotype in terms of chromosome number (59 chromosomes), 
the frequency of metacentric chromosomes and the incidence of marker chromosomes, 
and these are clearly distinguishable from that of the normal canine cell [2, 8, 31, 44, 
47, 52, 63, 84, 86, 88]. The demonstration that the karyotypes of CTVTs from different 
geographical regions are similar suggests that CTVT is transferred from one animal to 
another by transplantation of viable cells. The following findings strongly support the 
cellular transmission of CTVT and the idea that CTVT originated from one cell type: 
1. CTVTs from different geographical regions have the same number of chromosomes 
and similar frequency of metacentric chromosomes [2, 8, 31, 44, 47, 52, 63, 84, 86, 
88].
2. The number of chromosomes and the frequency of metacentric chromosomes are 
maintained after subsequent passages in vitro and in vivo [2].
3. The number of chromosomes of the primary tumour in the genitalia and the metastatic 
tumour in the brain are identical [3].
4. Banding pattern analysis of CTVT chromosomes revealed extensive structural 
rearrangements in the CTVT, and these rearrangements were identical in different 
tumours [66].
5. Southern blot analysis showed that CTVT from individual dogs from various regions 
contain identical rearranged gene (c-MCY oncogene) [5, 17, 48]. 
6. In a xenograft model of CTVT (XTVT) in NOD/SCID mice, XTVT cells retained 
the cytological and histological features of CTVT, as well as characteristic rearranged 
LINE/c-MYC junction [34, 35]. This constancy and stability of CTVT karyotype might 
contribute to the easy transplantability of this tumour.
  The contagious nature of CTVT has led to numerous attempts to 
demonstrate a causative oncogenic viral agent. Some researchers have demonstrated by 
electron microscopy virus like particles within some CTVT cells [7, 49, 50]. Adams et 
al., and Gonzales-Angulo and Hernandex-Jauregui found type-C viral particles in tissue 
culture-grown CTVT tumour cells [1, 32]. Cell-free transmission has been reported 
[50], suggesting an infectious agent as a cause. Contrary to these findings, Cockrill and 
Beasley, and Hill et al., using ultrastructural techniques, were unable to observe any 
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viral-like particles within the CTVT cells [18, 38]. However, they observed lamellar 
arrays in CTVT resembling structures described by Lombard and Cabanie [50], and 
Amber et al. [7] as viral like-inclusion bodies. The presence of these viral like particles 
in CTVT could be incidental findings. Up to now, no virus has been isolated from CTVT 
cells.
  In summary, it is apparent from all these investigations that no 
reproducible evidence is available to demonstrate viral aetiology of this CTVT. In 
contrast, cytogenetic and immunological (see below) studies strongly suggest that 
CTVT is a cell-transmitted neoplasm. However, the etiologic agent that originally 
induced the CTVT is still unknown.
CTVT immunophenotype 
In haematoxylin- and eosin-stained sections, progressive CTVT is characterized by 
compact masses of neoplastic cells arranged in a diffuse pattern and supported by thin 
trabeculae of fibrovascular tissue. The tumour cells are round or polyhedral with a large, 
round, central nucleus, usually containing a single prominent nucleolus (Figure 1). The 
cytoplasm is slightly granular, vacuolated and eosinophilic with indistinct borders. 
Because the histological features and ultrastructural features of CTVT cells does not 
clarify the cell of origin, CTVT originally has been described as a lymphosarcoma, a 
tumour of neuro-ectodermal or aortic origin, a histiocytoma, an infective granuloma 
or a round cell sarcoma [24, 46, 65, 80]. Most canine round cell tumours have been 
immunocharacterized using several tumour markers  [25, 29, 58, 81], making it easy 
for accurate diagnosis and classification. Although CTVT has been subjected to 
immunohistochemical studies with several tumour markers (Table I), its origin and the 
immunophenotype still remain uncertain. However, immunohistochemical studies with 
a panel of several antibodies have managed to rule out some of the early suggestions. 
Figure 1. CTVT during progressive stage. The tumour 
consists of sheets of polyhedral cells, with large, central 
nucleus, containing a central nucleolus. H&E. x 200.
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  From the data shown in Table I, CTVT cells are negative for keratins, 
α-smooth muscle actin, desmin, CD3, immunoglobulins G and M, λ-light chains and κ-
light chains, and this means that an epithelial, smooth muscle, and T- and B lymphocyte 
origin can be ruled out. Antibodies against CD3, surface immunoglobulins G and M, 
λ-light chains and κ-light chains are useful for differentiating CTVT from lymphomas 
and plasma cell tumours. Lysozyme and alpha-anti-trypsin (AAT) have been considered 
good markers for benign and malignant histiocytes [79], and these antigens are not 
expressed by other mesenchymal cells [73]. ACM1 is a canine specific antibody 
recognizing a fixation resistance epitope present in the majority of canine mononuclear 
phagocyte stem cell [54]. 
  In summary, the phenotypic origin of CTVT is not yet clear, but 
the expression of ACMI, lysozyme and AAT suggest a histiocytic origin because 
these antigens are not expressed by other mesenchymal round cells, except those of 
hystiocytic origin [54, 73]. Because there is no significant difference between the 
Table 1. Antibodies and their cellular specificity used in the immunohistochemical characterization of 
CTVT (Marchal et al. [54] and  Mozos et al. [59]).
Antibody specificity Cellular specificity Result
Keratin
Vimentin
Desmin
α-smooth muscle actin
CD3
IgG & IgM
λ -light chains
κ-light chains
Lysozyme
ACM1
Α-1-antitrypsin
Epithelial cells
Mesechymal cells 
Muscle cells
Smooth muscle cells
T-lymphocytes
B-lymphocytes
B-lymphocytes
B-lymphocytes
Histiocytes
Histiocytes
Histiocytes
-
+
-
- 
-
-
-
-
+
+ 
+
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immunophenotype of histiocytomas and CTVT, the differential diagnosis should be 
based on clinical and histopathologic criteria.
Immunobiology; A model for tumor immunology 
In clinical patients, CTVT grows rapidly after sexual transmission, followed by 
indolent local tumour growth or progression with metastasis: some tumours regress 
spontaneously [72], and this is followed by transplantation immunity [16]. In 
experimental cases, CTVT evades immuno-surveillance and grows progressively for 
12 weeks, until it becomes vulnerable and subject to the host’s anti-tumour immune 
response [43]. In immunocompromised animals and puppies, there is metastasis [21]. 
The frequent spontaneous regression of both natural and experimentally transplanted 
CTVT suggests that the immune response against the tumour plays a major role in 
determining the course of the disease. CTVT evokes both humoral and cell-mediated 
immune response, and also transplantation immunity in immunologically competent 
host, which prevents subsequent tumours [28, 57, 68]. Studies done on aspects of the 
immune response, including the role of tumour-associated antigens, humoral and cell-
mediated immunity, and MHC antigens are mentioned below. 
4.1. CTVT associated-antigens and humoral immunity
CTVT has been reported to be antigenic and to evoke transplantation immunity in the 
host that rejected the tumour [11]. A tumour antigen associated with CTVT has been 
identified and partially characterized [68]. The presence of this tumour-associated 
antigen has been confirmed by immunoelectron microscopic localization during the 
progressive, steady and regressive stages by using antibodies against the tumour-
associated antigen [39].  It has been shown that following transplantation of CTVT, this 
tumour-associated antigen is shed into circulation during the progressive stage [68]. The 
amount of this antigen in serum increased proportionately with tumour volume, and the 
antigen could no longer be detected in sera 48-72 hours after surgical removal of the 
tumour [92]. This suggests that this antigen and its complexes may be responsible, at 
least partially, for blocking the host’s immune mechanism as suggested in other tumours 
[13]. 
  There is convincing evidence that humoral immunity plays a role in 
CTVT progression. Passive transfer of post-regression sera to CTVT-bearing dogs was 
shown to inhibit and prevent tumour development if administered simultaneously with 
tumour transplantation [76]. Moreover, the growth of CTVT is inhibited in puppies born 
to dams that are immunized with CTVT before or during pregnancy [91]. Furthermore, 
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antibodies against membrane-associated antigens can be demonstrated [11, 19]. Perez 
et al. also found more B-lymphocytes and plasma cells in intra- and peri-tumoral 
inflammatory infiltrates of regressive tumours than of progressive tumours [72]. Studies 
by Fenton and Yang, showed that more CTVT cells have membrane-bound antibodies 
in the steady and regression states than in the progression state [28]. In addition, the 
presence of such antibodies in adult dogs, but the absence in the puppies with tumour 
metastasis [28], suggest the importance of humoral immunity in the progression of this 
tumour.
  In summary, it appears that membrane-associated transplantation 
antigens are expressed on the surface of CTVT cells. However, whether the immune 
response towards these antigens plays a role in the induction of spontaneous regression 
of CTVT is not yet established. Because these tumour-associated antigens are expressed 
during the progressive, steady and regressive phases, they are not likely to play an 
important role in the spontaneous regression.
4.2. Cell mediated immunity and major histocompatibility (MHC) antigens
Tumours are frequently infiltrated by T-lymphocytes and natural killer (NK) cells [15]. 
Increased numbers of tumour infiltrating lymphocytes (TILs) (Figure 2), particularly 
T-lymphocytes, are associated with tumour regression in CTVT [43, 57, 85]. Anti-
tumour effects of TIL have been intensively studied. In human renal cell carcinoma, 
proliferating intratumoural CD8(+) lymphocytes indicated effective anti-tumour 
immunity [64]. The T-cell cytotoxicity is believed to be associated with apoptosis [10] 
and apoptosis is increased in regressing CTVTs [33].
  Peripheral blood lymphocytes (PBL) of dogs in which CTVT had 
regressed, have been shown to be cytotoxic to the tumour cells in contrast to PBL of 
normal dogs and animals during progressive tumour growth [20]. In addition, sera of 
dogs in which the CTVT had regressed could be demonstrated to mediate antibody-
Figure 2. CTVT during the early regression stage. 
Numerous tumour infiltrating lymphocytes (TILs). 
H&E. x 400.
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dependent cellular cytotoxicity (ADCC) with normal dog lymphocytes or cytotoxic 
PBL as effector cells [20]. 
  CTVT can be transplanted with intact viable cells across MHC 
barriers within the species, and even to other members of the canine family, such as 
foxes, coyotes, and wolves. The effector functions of both T-lymphocytes and natural 
killer (NK) cells depend on the level of MHC antigens expressed on the surface of 
tumour cells. MHC antigens are membrane glycoproteins that display peptide antigen 
to T-lymphocytes. MHC antigens function as cell surface markers to signal cytotoxic 
(MHC class I) and helper-T-lymphocytes (MHC class II), and are indispensable for the 
presentation of cells bearing “foreign” antigens to cytotoxic T-lymphocytes [95]. MHC 
class I antigens play a key role in host defence against cells expressing foreign antigens. 
Several naturally occurring tumours and virally transformed cells show an overall 
suppression of these surface antigens [27]. Since the MHC class I antigens are required 
in the presentation of neoantigens on tumour cells to the cytotoxic T-lymphocytes, 
their absence from the cell surface may lead to the escape of these tumours from 
immunosurveillance. CTVT cells are not rejected as first set allograft. The reason for 
this is still not clearly established. After 2 to 4 months of progressive growth, the tumour 
regresses spontaneously in immunocompetent adult dogs, or results in metastasis in 
puppies and immunosuppressed adult dogs.                       
  The mechanisms of how the CTVT manage to overcome MHC 
barriers so successfully for such a long period and yet succumb later are not known. 
Recent studies have demonstrated that CTVT cells in the progressive stage lacked 
the expression of both MHC class I and class II antigens, whereas 30 to 40% of the 
tumour cells in the regressive stage expressed these antigens [72, 90]. Certain human 
malignant tumours, including eccrine porocarcinomas [41], some skin tumours [40] 
and cervical carcinomas [22], have markedly reduced or non-detectable levels of MHC 
class I antigens (in contrast to their benign and normal cellular counterparts), suggesting 
a possible mechanism for their escape from immune surveillance. In addition, 
transfections of functional MHC class I antigens into highly tumorigenic adenovirus-
transformed cells, which originally failed to express MHC class I antigens, abrogated 
the antigenicity of these cells [83]. This strongly suggests that the lack of expression of 
MHC class I antigens in the progressive stage may be responsible, at least in part, for 
the ‘universal uptake’ and progressive growth of CTVT in allogenenic host.  
  The re-expression of MHC antigens in regressive stage might be 
responsible for the spontaneous regression of CTVT after a progressive growth. The 
precise mechanism of how CTVT cells are activated to re-express MHC antigens in the 
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regressive phase is yet to be confirmed. However, several cancer cell lines can be activated 
by γ-interferon to express MHC antigens [94]. It has been shown that co-culturing CTVT 
cells with TILs or culturing with TILs-conditioned media promote the expression of 
MHC classes I and II antigens by CTVT cells [43]. From these findings, it is reasonable 
to assume that modulation of the re-expression of MHC antigens is by soluble factors or 
cytokines released by TILs. This may underline the efficacy of interferon in the treatment 
of CTVT and other malignancies. Greater understanding of the cytokines or growth 
factors produced by TILs could lead to novel therapeutic regimens for treating tumours.
  Heat shock proteins (HSPs) may play a role in the re-expression of 
MHC antigens in CTVT. HSPs are among the most abundant proteins in living cells 
and become even more abundant during stress. In cells, HSPs are actively associated 
with antigen presentation [87], lytic activities of natural killer cells [14], and cytotoxic 
T-lymphocytes [87]. Transfection of B16 melanoma cells with HSP 65 dramatically 
increases levels of class MHC antigens on their surface, and these transfected cells are 
effectively lysed by alloreactive cytotoxic T-lymphocytes [87]. In CTVT, increased 
levels of HSP 60 in cells in the regression phase has been observed [17], suggesting 
HSPs may play a role in the regression.
Although cytotoxic T-lymphocytes recognize tumour-associated antigenic peptides 
presented by MHC class I molecules, natural killer (NK) cells are cytotoxic for tumour 
cells that have lost MHC class I expression. The loss of MHC class I may activate NK 
cells leading to tumour cell destruction [75]. NK cells destroy infected and malignant 
cell cells via two mechanisms: antibody-dependent cellular cytotoxicity and killer-
activating and killer inhibitory receptors [12]. The killer-inhibitory receptors recognize 
MHC class I molecules. This recognition overrides the effector function of NK cells and 
the target cell is not destroyed. Thus, in absence of MHC class I molecules, as in CTVT 
cells in the progression stage, an inhibitory signal from the killer-inhibitory receptor is 
not generated and the NK cell should kill the abnormal cells. In fact NK cells are cells 
specialized in killing cells that no longer express MHC class I antigens. The mechanism 
of how CTVT cells escape immunosurvillance by NK cells is not clear. Some tumours 
like melanoma cells express ectopic non-classical MHC class I, such as HLA-G [70, 71], 
which may block the activating functions of NK cells [4]. Further research is needed for 
the mechanism that CTVT in the progressive phase CTVT utilise to avoid NK activity.
  In conclusion, the mechanisms of how CTVT cells manage to overcome 
histocompatibility barriers so successfully for a long period and yet succumb later are 
not clear. It seems as if CTVT has undergone immunoselection processes, which has 
resulted in its ability to escape from host’s immune surveillance. The following factors 
may play a role:                               
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1. Lack of expression or down regulation of MHC Class I and Class II antigens on cells 
in the progressive stage of the tumour [90].                                        
2. Expression of ectopic non-classical MHC antigens, such as HLA-G to escape NK cell 
immunosurveillance.                              
3. Shedding of tumour-associated antigen [68]. 
4. Formation of immune complexes [69].                                         
5. Production of blocking factors [11] to escape recognition and to block the hosts’ 
immune system.                            
Evaluation of CTVT stage 
CTVT responds well to chemotherapy using cyclophosphamide, methotrexate, or 
vincristine [6]. Treatment could be more properly selected if the stage of growth is 
determined. Besides clinical observation and monitoring, evaluation of the growth stage 
of CTVT may be very difficult. Assessment of proliferative and apoptotic fractions of 
CTVT has shown that during tumour regression, tumour cell proliferation ceased and 
apoptosis increased [33]. TILs are increased during the regression phase of CTVT [72], 
and therefore, quantitation of TILs may be used to determine the stage of CTVT. Since 
MHC antigens [72] and heat shock proteins [17] are increased during regression of 
CTVT, these may also be used to evaluate the stage of growth. During the regressive 
stage, there is collapse of the tumour and replacement of the tumour parenchyma 
by fibrovascular stroma (Figure 3). The stromal cell type and extracellular matrix 
components of the progressing and regressing tumours have not been investigated. 
Different ECM components may accumulate during different stages of the tumours 
(like in malignant vs benign tumours) in some human [45] and canine [61] tumours. No 
studies have analyzed the temporal expression of extracellular matrix components like 
tenascin, hyaluronan and versican that play an important role in tumour progression in 
some human [78] and canine tumours [26, 60].
Fig 3. CTVT during the regressive stage. Collapse of the 
tumour parenchyma and replacement by fibrovascular 
stroma. H&E. x 200.
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Immunotherapy
Immunotherapy is receiving interest as an alternative or adjuvant approach to the 
treatment of many malignancies. The potential for immune modulation as a treatment of 
tumours is a focus of cancer researchers throughout the world. Efficient chemotherapy 
protocols for CTVT are known, but there is little information on the presence of both 
an efficient prophylactic approach to prevent CTVT and immunotherapeutic agents 
effective against CTVT. Cell-mediated immunity accompanies chemotherapy-associated 
regression in CTVT [33]. Immunostimulators (paramunity activators) have been tried in 
several tumours and some of them have produced positive results [9, 62]. Paramunity 
activators are given with the intention of enhancing the non-specific immune reactivity 
to the host, and this non-specific immunity is both humoral and cellular [55].  Since 
humoral and cellular immunity is known to play an important role in the regression of 
CTVT [20, 56]), paramunity activators are expected to be effective in both prophylaxis 
and treatment of this tumour.
  Very few paramunity activators have been tried on CTVT. 
Immunotherapy studies with bacillus Calmette-Guérin (BCG) have been done [36, 42, 
82]. Intra-lesional BCG therapy of CTVT is highly effective in causing regression [36, 
82]. The results of these studies clearly demonstrate that the clinical course of CTVT is 
determined by the immune response toward the tumour. However, routine use of BCG 
immunotherapy for CTVT has not been reported.
  Parvovirus vaccine has been shown to prevent experimental tumour 
transplantation when the vaccine was inoculated simultaneously with the tumour [93], 
but the routine use of this vaccine is also not reported. Local injection of interleukin-2 
has been tried for immunotherapy with 32% success [67]. The mechanism how IL-
2 causes regression of the tumour is not clear. IL-2 stimulates synthesis of in vivo 
production of INF-γ [51], and INF-γ is a well known factor that up-regulates expression 
of MHC molecules [77].
Conclusion 
We have discussed the cytogenetic origin, the immunophenotype of CTVT, and the 
events occurring during progression and regression phase, and how these events are 
linked to the unique behaviour of this tumour. There are encouraging results on how 
this tumour is initially accepted by the host and later rejected. However, many questions 
still need to be answered: Is the easy transplantability of CTVT due to the constancy 
and stability of its odd karyotype or a consequence of an increase in the resistance of the 
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spontaneous tumour to the iso-immune host or lack of MHC expression? It thus appears 
important to consider the specific roles of MHC antigens, HLA-G expression in CTVT 
and other tumours when considering future therapeutic choices of immunomodulation 
strategies intended to complement cancer treatments. What is the role of the tumour 
stroma (fibroblasts, vessels and extracellular matrix components) in the progression of 
CTVT? Answering some of these questions might help coming up with a clue on the 
interaction between the host and tumour cell and how tumour cells are able to escape 
the immmuno-surveillance. 
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Abstract
Stromal cells and extracellular matrix (ECM) components are important for tumour 
cell behaviour. Little is known about the role of stromal cells and ECM components in 
the progression and regression of spontaneous canine transmissible venereal tumour 
(CTVT). In this study, the stromal cell type was determined by immunohistochemical 
labelling with antibodies to desmin, vimentin and α-smooth muscle actin (α-SMA) 
during the progressive and regressive stages of spontaneous CTVT. The distribution 
of ECM components tenascin-C, chondroitin sulphate and versican were determined 
immunohistochemically, and hyaluronan distribution was determined using a 
biotinylated protein complex with specific affinity for hyaluronan. Stromal cells of 
tumours in both the progressive and regressive stage were positive for vimentin and 
negative for desmin. The number of stromal cells expressing α-SMA was significantly 
higher (P=0.001) in regressing tumours, than progressing tumours. These results 
suggest that the modulation of stromal cells that occurs during the regression of CTVT 
is similar to that occurring during wound healing. Tenascin-C was weakly expressed in 
the stroma of tumours in the progressive stage and in regions of the regressing tumours 
with tumour infiltrating lymphocytes (TILs), but intensely expressed in the stroma 
of tumours in late regressive stage. In addition, tenascin-C was also expressed in the 
cytoplasm of some tumour cells in the late regressive stage. A strong stromal tenascin-
C intensity was significantly associated with regressing tumours (P=0.001).  Strong 
stromal hyaluronan intensity and a high proportion of hyaluronan-positive tumour cells 
were significantly associated with progressing tumours (P=0.001). This suggests that 
hyaluronan is involved in the growth of the tumour. There was no significant difference 
in the expression of chondroitin sulphate and versican in progressing and regressing 
tumours. 
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Introduction
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious round 
cell neoplasm of dogs of both sexes which can be transplanted with intact viable cells 
across major histocompatibility complex barriers within species, and even to other canids 
such as foxes, coyotes and jackals (Higgins, 1966). It is the only known transplantable 
tumour. In both natural and experimentally induced cases, the tumour exhibits a 
predictable growth pattern – progressive growth, stasis and regression. The spontaneous 
regression of CTVT may be regulated by a variety of factors, including products of 
neoplastic cells, stromal cells and tumour infiltrating lymphocytes (TILs). In addition, 
extracellular matrix (ECM) components and cytokines regulate cell-microenvironment 
interaction, which, in turn, modulate tumour progression and tumour cell activities 
(Hynes, 1992; Albelda, 1993). The tumour is frequently characterized by the presence 
of numerous TILs during the early regressive stage, and by the replacement of tumour 
parenchyma by fibrovascular stroma during the late regressive stage (Gonzalez et al., 
2000). Therefore, this tumour represents a neoplastic microenvironment useful in the 
investigation of the role of stromal cells, ECM components and host immune response 
in tumour progression. 
   The fibroblast is the most abundant cell type in normal connective 
tissue. Some fibroblasts express features of smooth muscle differentiation, and these 
are called myofibroblasts, and are identified by expression of α-smooth muscle actin 
(α-SMA) (Sappino et al., 1990). Myofibroblasts play an important role in wound repair 
and tumour progression through their production of growth factors and cytokines. 
Myofibroblasts also repair or remodel the ECM through synthesis of proteoglycans 
and glycoproteins. During the regression of CTVT, there is an increase in the volume 
of the stromal tissue and replacement of the tumour parenchyma. The phenotype of the 
stromal cells in the progressing and regressing CTVT, to our knowledge, has not been 
studied.
  Tenascin-C is a large glycoprotein that is transiently expressed during 
embryogenesis, wound healing and in neoplastic conditions (Chiquet-Ehrismann et al., 
1986; Erickson, 1993). It is thought to be involved in many cellular functions including 
adhesion, proliferation and tumour metastasis (Erickson and Bourdon, 1989; Orend and 
Chiquet-Erhismann, 2000). Tenascin-C expression is altered in many solid tumours 
(Mackie et al., 1987), suggesting that it might be associated with tumour progression.
  Hyaluronan is a linear unsulphated glycosaminoglycan synthesized on 
the cytoplasmic side in the plasma membrane. Hyaluronan has been associated with 
many different cellular processes including cell adhesion, aggregation, proliferation, 
inflammation, locomotion and migration (Knudson and Knudson, 1993). Hyaluronan 
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overproduction is a diagnostic or prognostic factor for several types of human cancer, 
including breast (Auvinen et al., 2000), thyroid (Böhm et al., 2002), ovarian (Anttila et 
al., 2000), and colorectal (Ropponen et al., 1998) cancers. 
  Changes in the level and structure of the glycosaminoglycans side 
chains of proteoglycans, such as elevated expression of chondroitin sulphate, have 
been associated with the progression of malignancy in various human tumours 
(Adany et al., 1990; Yeo et al., 1990, Cohen et al., 1994). Measurement of chondroitin 
sulphate levels in the pertumoral stroma of human prostate cancer can predict tumour 
progression (Ricciardelli et al., 1999). Versican, a member of the large aggregating 
chondroitin sulphate proteoglycan family, is a recognized anti-cell adhesive 
molecule involved in regulating cell motility on ECM components (Yamagata et al., 
1989; Evanko et al., 1999). Versican interacts with tenascin (Aspberg et al., 1997) 
and hyaluronan (LeBaron et al., 1992), and may play an important role in CTVT 
progression. 
  Up to now, research on CTVT biology has focused only on the 
neoplastic cells and TILs, while the stromal cells and the ECM components are 
thought to lack major biological activities and clinical significance. The objectives of 
the present study were 1) to assess the phenotype of stromal cells, and 2) to assess the 
expression of ECM components (tenascin-C, hyaluronan, chondroitin sulphate and 
versican) during the progression and regression stages of CTVT.
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Materials and Methods
Case material
Dogs (13 males, 16 females) with natural CTVT restricted to the external genital 
membranes were observed for 2 weeks, and the size of the tumours were measured. The 
tumours were classified into two groups according their stage of clinical growth. The 
first group included 13 tumours, which showed increase an in size when the tumours 
were surgically excised, and these were classified as progressing tumours. The second 
group included 16 tumours, which showed a constant or decreasing size when the 
tumours were excised, and these were classified as regressing tumours. Tissue samples 
were fixed in 10% buffered formalin for 24 h and embedded in paraffin. Three to 6 
sections, representative of each tumour were stained by haematoxylin and eosin for 
histopathological study.
Immunohistochemical and histochemical labelling 
In each case, 4-μm sections of formalin-fixed, paraffin wax-embedded tissues were 
mounted on poly-L-lysine coated slides. After de-waxing and rehydration, the 
sections were treated with H
2
O
2
 0.5% in methanol for 30 min to inactivate the intrinsic 
peroxidase activity. For labelling of antigens of tenascin-C and versican, deparaffinized 
sections were pre-treated with chondroitinase 0.2 U/ml ABC (Seikagaku, Kogyo, 
Tokyo, Japan) in 0.2 M Tris-HCL buffer (pH 8.0) at 37oC for 1 h. The slides were 
preincubated with normal horse serum 10% for 30 min before incubation with primary 
antibody (anti-vimentin, desmin, α-SMA, tenascin-C, chondroitin sulphate and 
versican) or biotinylated hyaluronan binding complex at 4oC overnight. Table 1 lists 
the antibodies and binding protein complex used in this study, their source and the 
specific dilutions. All sections were then incubated with horse anti-mouse biotin and 
avidin-biotin peroxidase complex (Vector, Burlingame, CA, USA). Colour reactions 
were developed in 3-3’-diaminobenzidine containing 0.01% hydrogen peroxide, and 
the sections were counterstained with haematoxylin for light microscopic examination. 
Negative controls consisted of serial sections incubated with buffer alone or purified 
mouse immunoglobulin instead of primary antibody. Each run also included a positive 
control slide of tissue previously demonstrated to be strongly positive for the above 
components.
Evaluation of labelling and statistical analysis
The sections were examined using a dual-head microscope simultaneously by two 
observers. Evaluation of the labelling intensity or the number of cells labelled was 
performed by either scoring the entire lesion or at least 10 representative high power 
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fields.  The labelling of α-SMA in stromal cells was graded as negative (no stromal cells 
positive), weak (<25% cells positive), moderate (25-50% cells positive), and strong 
(>50) and recorded as 0-3, respectively. The level of stromal tenascin-C, hyaluronan, 
chondroitin sulphate and versican in the tumours was graded as negative, weak, moderate 
or strong and recorded as 0-3, respectively. The expression of hyaluronan in tumour 
cells was graded as weak (<25% cells positive), moderate (25-50% cells positive), and 
strong (>50%) positive and recorded as 1-3, respectively. The relationship between the 
stage of the tumour and stromal cell type or tenascin-C, chondroitin sulphate, versican 
and hyaluronan intensity was tested using χ2 analysis of SAS (1996).
Results
Histology
In the progressive stage, the tumours consisted of round cells, with little connective 
tissue stroma (Fig. 1). The stromal cells were spindle shaped with an elongated nucleus. 
During the early regression stage, there was infiltration of the tumours by tumour-
infiltrating lymphocytes (TILs). These TILs were either diffusely distributed (Fig. 2) or 
associated with areas with fibrovascular stroma. In the late regression stage, there was 
collapse of the tumour parenchyma and replacement by fibrous stroma (Fig. 3). 
Stromal cells; Vimentin, Desmin, α-smooth muscle-actin  expression
In all the tumours, all the stromal cells were strongly immunolabelled by vimentin 
and negative for desmin. α-smooth muscle actin was positive in the media of all blood 
vessels. Stromal cells were positive for α-SMA in 4/13 (30%) of the tumours in the 
progressive stage (Fig. 4), and all (100%) of the tumours in the regression stage (Fig. 
5). The number of stromal cell expressing α-SMA was significantly higher (P=0.001) 
in regressing tumours than progressing tumours (Table 2). In all the cases, tumour cells 
Fig. 1. Canine transmissible venereal tumour (CTVT) 
during the progression stage. The tumour consists 
of round cells, with little connective tissue stroma. 
Heamatoxylin and eosin (HE). x 200.
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Fig. 2. CTVT during early regression stage. Presence of tumour-infiltrating lymphocytes (TILs). HE. x 
200.
Fig. 3. CTVT during late regression stage. Collapse of the tumour parenchyma and replacement by fibrous 
stroma. HE. x 200.
Fig. 4. CTVT during progression stage immunolabelled for α-SMA. There is no immunolabelling of 
stromal cells by α-SMA. Avidin-biotin peroxidase complex (ABC), haematoxylin counter-stain. x 200
Fig. 5. CTVT during regression stage immunolabelled for α-SMA. There is a strong immunolabelling of 
stroma by α-SMA. ABC, haematoxylin counter-stain. x 200
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were positive for vimentin and negative for desmin and α-SMA.
Tenascin-C expression
Tenascin-C labelling was present in the stroma in 9/13 (69%) of the tumours in the 
progressing stage. In the early regression stage, tenascin-C was labelled in the stroma 
of all the tumours except in areas with TILs. In the late regression phase, tenascin-C 
was intensely labelled in the stroma of all tumours (Fig. 6). There was no tenascin-
C labelling in the tumour cells during the progressing stage, while 8/16 (50%) of the 
regressing tumours expressed granular cytoplasmic tenascin-C (Fig. 6). A strong stromal 
tenascin-C intensity was significantly associated with regressing tumours (P=0.001).  
Hyaluronan, chondroitin sulphate and versican expression
Hyaluronan was immunolabelled in the stroma of all tumours. Strong stromal 
hyaluronan intensity was significantly associated with progressing tumours (P=0.001). 
In addition to stromal labelling, hyaluronan labelling was expressed on cell membranes 
and cytoplasm in all the tumours (Fig. 7). A high proportion of hyaluronan-positive 
tumour cells was significantly associated with progressing tumours (P=0.001). In no 
cases were TILs positive for hyaluronan.
  Chondroitin sulphate was expressed in the stroma of all tumours and 
on the outer membrane of tumour cells regardless of their stage of progression. Versican 
was expressed in the stroma of only 5/29 (17%) tumours (2 regressing and 3 in the late 
progressive stage), and was not expressed in tumour cells. The intensity of stromal 
chondroitin sulphate and versican was not significantly related to the growth stage of 
the tumour. 
Fig. 7. CTVT during the progression stage 
immunolabelled for hyaluronan. There strong is 
membranous and cytoplasm labelling of tumour 
cells. ABC, haematoxylin counter-stain. x 200. 
(refer to colour picture page 156)
Fig. 6. CTVT during regression stage 
immunolabelled for tenascin-C. There is a 
strong immunolabelling of stroma by tenascin-
C. Note there is also granular cytoplasmic 
labelling of some tumour cells. ABC, 
haematoxylin counter-stain. x 200.
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Discussion
This study, to our knowledge, is the first study on the role of stromal cells and 
extracellular matrix (ECM) components on the progression of CTVT. The study shows 
that the stromal cells and ECM components are different in the different stages of 
growth of CTVT, and this may influence tumour progression. 
  We used immunolabelling with vimentin, desmin and α-smooth muscle 
actin (α-SMA) to identify myofibroblasts, and our results showed that there was a 
higher number of myofibroblasts during the regression than the progression stage. 
Myofibroblasts have been implicated in a variety of pathological conditions involving 
tissue remodelling, including wound healing, and stromal reactions of tumours (Martin, 
1997; Serini and Gabbiani, 1999). As the appearance of myofibroblasts occurred during 
the regression stage and coincided with TILs, it seems quite likely that mediators 
produced by TILs are important for controlling and development of myofibroblasts, 
or the increase in myofibroblasts and TILs may be the consequence of the same factor 
produced by tumour cells. The mediators that direct the stromal reaction were not 
determined in this study. TGF-β emerges as a strong candidate because of its key 
regulatory role in wound repair and stromal cell biology (Roberts and Sporn, 1993). It is 
also possible that TILs communicate with fibroblasts through intimate physical contacts.
  Tenascin-C is a multifunctional glycoprotein, participating in cell 
adhesion, repulsion, and epithelial shedding from surfaces. In our study, we observed an 
increase in stromal tenascin-C expression from progressive to regressive stage. During the 
regression stage of CTVT, there is destruction of the tumour parenchyma and extensive 
remodelling of the stroma. Tenascin-C expression is increased in processes like wound 
healing (Mackie et al., 1988) and embryogenesis (Chiquet-Ehrismann et al., 1986), 
where there is extensive tissue remodelling. The increased expression of tenascin-C in 
regressing tumours probably enhances proliferation of stromal cells (myofibroblasts). 
There was co-localization of tenascin-C and myofibroblasts, suggesting that these cells 
are responsible for the secretion of tenascin-C. These observations in CTVT accorded 
with the reported tenascin-C expression in canine gastrointestinal epithelial tumours, 
where tenascin was co-localized with myofibroblasts (Mukaratirwa et al., 2003). In 
tumours, myofibroblasts are responsible for the elaboration of most components of 
the extracellular matrix including tenascin-C (Hanamura et al., 1997). The presence of 
cytoplasmic tenascin-C immunolabelling in tumour cells suggests that CTVT cells also 
secrete tenascin-C.  
  In areas with TILs, tenascin-C expression was absent. Since tenascin-
C suppress T cell proliferation and cytokine production (Puente Navazo et al., 2001), 
its absence in these areas would allow TILs to play a primary role in the spontaneous 
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regression of CTVT. Similar results have been observed in transgenic mice, where in 
tenascin-C-null mice, stromal components of spontaneous mammary tumours contained 
more monocytes/macrophages than from tenascin-C wild type mice (Talts et al., 1999). 
TILs are considered to be of primary importance in the spontaneous regression of 
CTVT (Mizuno et al., 1989).
  The results indicate that hyaluronan is expressed in the stroma of all CTVTs, 
irrespective of the stage of growth. The presence of hyaluronan in the stroma may 
give tumour cells a growth advantage since hyaluronan creates hydrated matrices, 
which enhance cell proliferation and locomotion (Knudson and Knudson, 1990). 
There was a significant relation between tumour cell-associated (membranous and 
cytoplasmic) hyaluronan expression with the stage of the tumour. Cell membrane-
associated hyaluronan may give CTVT cells a growth advantage, as hyaluronan 
shields cells against apoptosis (Yasuda et al., 2001), and possibly also mask tumour-
associated antigens and major histocompatibility antigens on tumour cell surface. 
When glioma cells were cultured with lymphocytes, it was observed that the cancer 
cells were surrounded by a pericelluar coat containing hyaluronan, which increased the 
resistance of them to immune attack (Gately et al., 1984). A similar process possibly 
occurs during the progressive stage of CTVT. The cytoplasmic hyaluronan may support 
tumour cell proliferation, perhaps through its intracellular receptors RHAMM and 
CD44. RHAMM interact with microtubules and actin filaments in the cell replication 
interphase and dividing cells, possibly interfering with cell proliferation (Assmann et 
al., 1999). The accumulation of hyaluronan in the stroma and CTVT cells may offer 
possibilities of therapeutic interventions using hyaluronan degrading agents or agents 
which specifically inhibit hyaluronan synthesis, as suggested by Auvinen et al., (2000). 
Hyaluronidase has been successfully used to enhance the penetration of cytostatic drugs 
in human bladder carcinomas (Höbarth et al., 1992), squamous cell carcinoma (Kohno 
et al., 1994) and breast cancer (Beckenlehner et al., 1992). It will be interesting to test 
the effect of combined use of hyaluronidase with the commonly used chemotheraupetic 
drugs (vincristine and cyclophosphamide) in the treatment of CTVT.
   Our results showed that chondroitin sulphate proteoglycans were 
expressed in the stroma and tumour cells of both progressing and regressing tumours. 
The nature of the proteoglycans involved in the increase in chondroitin sulphate 
proteoglycans in these tumours is unknown, but our results suggest that versican is not 
responsible for this chondroitin sulphate proteoglycans accumulation 
  In conclusion, the stromal reaction occurring in regressing CTVTs 
appears to be comparable, if not identical, to generic wound repair, and stromal tenascin-
C and hyaluronan, and cell associated hyaluronan may be markers of the growth stage 
of the tumour.  We, therefore, suggest that further clinical studies on the synthesis and 
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regulation of tenascin-C and hyaluronan in CTVT are clearly warranted.
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Abstract
Stromal cells interact with cancer cells through direct cell-to-cell contact, and via 
production of cytokines and extracellular matrix (ECM) components. These interactions 
influence tumour cell proliferation and differentiation, stromal cell phenotypic 
differentiation, and secretion of ECM components. In this study we have established a 
monolayer and a 3-dimensional cell-to-cell interaction model between canine mammary 
stromal cells and human colonic carcinoma cell lines (Caco-2 and HT-29) to investigate 
paracrine effects of tumour cells on stromal cells and vice versa on (i) tumour cell 
differentiation, (ii) production of ECM components, and (iii) phenotypic differentiation 
of stromal cells. We showed that when Caco-2 or HT-29 cells are cultured in collagen 
gels, they form a few small solid unorganised cell clusters with no lumina, but when 
co-cultured with stromal cells, the tumour cells formed glandular structures with central 
lumina. Culturing of stromal cells, Caco-2, or HT-29 cells alone in both monolayers 
and gels resulted in weak tenascin-C expression in stromal cells and the HT-29 cells, 
and no expression in the Caco-2 cells. Co-culturing of stromal cells with tumour cells 
resulted in increased tenascin expression in the stromal cells and HT-29 cells, and 
induced expression of tenascin in the Caco-2 cells. This increased expression and 
induction of tenascin-C expression appeared to be mediated by transforming growth 
factor-beta (TGF-β) as shown by experiments blocking its effect with specific antiserum 
and adding it to the cultures. Culturing of stromal cells, Caco-2, or HT-29 cells alone 
in both monolayers and gels resulted in a weak expression of chondroitin sulphate 
(CS), chondroitin-6-sulphate (C-6-S) and versican in stromal cells, and no expression 
in Caco-2 and HT-29 cells. Co-culturing of stromal cells with tumour cells resulted in 
increased CS, C-6-S and versican expression in stromal cells. This tumour cell-induced 
expression of CS, C-6-S, and versican appeared to be mediated by TGF-β and platelet 
derived growth factor (PDGF). Coculturing of Caco-2 and HT-29 and stromal appeared 
to promote the transformation of stromal cells into myofibroblasts and this probably was 
mediated by TGF-β. These results suggest that TGF-β and PDGF represent / are part of 
a paracrine system involved in stromal-epithelial cell interaction important in stromal 
cell differentiation and ECM production. 
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Introduction
Activation of the host stromal microenvironment is predicted to be a critical step in 
epithelial tumour growth and progression. However, the specific mechanisms of stromal 
activation by tumour cells are not known, and the extent to which the stroma regulates 
the biology of tumorigenesis is not fully understood. Tumour progression occurs 
within a micro-ecosystem where cancer cells and stromal cells exchange proteinases 
and cytokines that promote growth directly through stimulation of proliferation and 
survival, as well as invasion through local proteolysis of the extracellular matrix (ECM). 
Evidence is accumulating that in addition to secretion of cytokines, tumour cells also 
influence stromal cells and vice versa through direct cell-to-cell contact (Zidar et al., 
2002), and production of ECM components (Donjacour and Cunha, 1991). 
  Extracellular matrix proteins in the tumours may positively or 
negatively influence tumour progression. Tenascin-C, a large hexameric glycoprotein 
is elevated in colorectal human tumours (Hanamura et al., 1997) and canine colorectal 
tumours (Mukaratirwa et al., 2003). The most prominent actions of tenascin-C include 
anti-adhesion effects (Chiquet-Ehrismann et al., 1989) and inhibition of cell attachment 
(Orend and Chiquet-Ehrismann, 2000), and these properties favour tumour cell motility 
and invasion. Chondroitin sulphate proteoglycans (CS-PGs) influence cell growth 
and differentiation (Caterson et al., 1990), and are elevated in malignant tumours 
(Hauptmann et al., 1995; Ricciardelli et al., 1997). Versican, a major chondroitin 
sulphate proteoglycan that is known to antagonize cell adhesion to pericellular matrix 
components (Wight, 2002), is also elevated in some tumours (Ricciardelli et al., 1998, 
2002; Touab et al., 2002), suggesting that increased deposition of versican in the stroma 
may contribute to progression of tumours.
  Pathological conditions associated with tissue remodelling and 
fibrogenesis (wound healing and neoplastic lesions) are characterized by the appearance 
of stromal cells with ultrastructural features intermediate between those of typical 
fibroblasts and those of smooth muscle cells. These fibroblasts display phenotypic and 
functional features of smooth muscle cells and hence are named myofibroblasts (Gabbiani 
et al., 1971, 1972, 1981). The function of myofibroblasts is still not clear. Because they 
are found in fibro-contractive diseases, e.g. in wound healing (Gabbiani et al., 1981) and 
in stromal reaction to tumours (Schurch et al., 1981; Sappino et al., 1988), it has been 
proposed that they are responsible for tissue retraction. Through their ability to secrete 
cytokines, chemokines, prostaglandins, growth factors, and ECM, myofibroblasts 
are thought to play critical roles in inflammation, growth, repair, and neoplasia 
(Desmouliére et al., 1993). In canine colorectal cancer, myofibroblasts were found to be 
located at the invasion front (Mukaratirwa et al., 2003). These observations suggest that 
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cytokines produced by invading tumour cells stimulate myofibroblast transformation. 
In canine colorectal tumours, there is co-localization of myofibroblasts and tenascin-C 
(Mukaratirwa et al., 2003), suggesting that myofibroblasts are responsible for tenascin 
secretion, or tenascin secretion and myofibroblast transformation are regulated in the 
same way/ in a coordinated manner. 
  The aim of this study was to investigate in vitro paracrine effects 
of tumour cells on stroma cells and vice versa on (i) tumour cell morphology and 
differentiation (ii) production of ECM components (tenascin-C, CS, C-6-S, and 
versican), and (iii) phenotypic differentiation of stromal cells to myofibroblasts. 
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Materials and Methods
Cell lines
Caco-2 cells (American Type Cell Collection, HTB37) and HT-29 cells (Lesuffleur et 
al., 1998) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Imperial 
Laboratories, Salisbury, UK) supplemented with heat inactivated 10% foetal calf serum 
(FCS), 100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulphate, and non-
essential amino acids (Sigma, St Louis, MO, USA). Both cell lines were incubated at 
37°C in an atmosphere of 5% CO
2
 and 95% air.
  For collection of tumour cell-conditioned medium, subconfluent 
monolayers of Caco-2 or HT-29 cells were washed 2 times with phosphate buffered 
salt solution (PBS) and once with DMEM without FCS, and subsequently cultured in 
DMEM without FCS for 24 h. The conditioned medium was stored at –70oC until use in 
studies on canine stromal cell monolayers and collagen gels.
Isolation of primary stromal cells from normal canine mammary tissue
Primary cultures of stromal cells were isolated from normal canine tissues using a 
technique based on that described by van Roozendaal et al. (1995) for the isolation 
of human breast fibroblasts. Fresh tissues were obtained from dogs with normal non-
lactating mammary gland. Each specimen was minced finely using a razor blade. The 
minced tissue was digested overnight with rocking motion at 37°C in 10 ml of 0.1% 
collagenase type I (clostridio-peptidases a; Sigma) in DMEM supplemented with 10% 
FCS, 100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulphate, and non-
essential amino acids (Sigma). The resulting cell suspension was centrifuged at 500 g 
for 5 min and the pellet resuspended in 5 ml of DMEM containing 10% FCS. The cell 
suspension was divided into two 25-cm2 tissue culture flasks. The cells were cultured at 
37°C in an atmosphere of 5% CO
2
 and 95% air in DMEM with 10% FCS, with medium 
being replaced at 24 h and then after every 2–3 days. Confluent monolayer cultures were 
observed after 9-12 days. Cells were used between passages 4 and 12. For stromal cell-
conditioned medium, subconfluent monolayers of stromal cells were washed 2 times 
with PBS and once with DMEM without FCS and subsequently cultured in DMEM 
without FCS for 24 h. The conditioned medium was stored at –70oC until used in studies 
on tumour cell monolayers and collagen gels
Culture and co-culture in monolayers on glass slides 
Cells trypsinized and diluted to 2 x 104 cells/ml for stromal cells and 1x 104 cells/ml for 
colonic tumour cells (Caco-2 and HT-29) in DMEM with 10% heat inactivated FCS, 
were seeded on multi-chambered glass slides. For co-cultures, mixtures of stromal cells 
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(2 x104 cells /ml) and Caco-2 and HT-29 cells (1 x 104 cells/ml) suspended in DMEM 
with 10% heat inactivated FCS were seeded on multi-chambered glass slides. The cells 
were allowed to attach overnight, then washed with PBS and switched to experimental 
conditions. For single cultures of Caco-2 cells and HT-29 and co-cultures with stromal 
cells, the cells were grown in DMEM with 10% FCS for 48 h, and then the media was 
replaced with DMEM without FCS supplemented with growth factors to be tested, or 
stromal cell-conditioned media for 48 h. For single cultures of stromal cells, after 24 h 
growth in DMEM with 10% FCS, the media were replaced with DMEM without FCS 
supplemented with growth factors to be tested, or Caco-2 or HT-29-conditioned media 
for 48 h. The following growth factors were used: transforming growth factor-β (TGF-β; 
3 ng/ml) (R&D Systems/Biermann, Bad Nauheim, Germany), platelet derived growth 
factor (PDGF; 50 ng/ml) (Sigma), epidermal growth factor (EGF; 10 ng/ml)(Sigma), 
insulin-like growth factor-I  (IGF-I; 10 ng/ml) (Sigma), and insulin-like growth factor-
I I (IGF-II; 50 ng/ml) (Gibco, Gaithersburg, MD, USA). After 48 h the slides were 
washed with PBS before the cells were fixed with ice-cold acetone for 10 min and 
stored at 4oC. Each experimental condition was assayed in triplicate, and at least three 
independent experiments were performed.
Cell culture and co-culture on collagen gels
Collagen was obtained from Wistar rat-tail tendons under sterile conditions. Tendons 
were dissolved in 0.1% acetic acid at 4oC under stirring for 48 h. The solution was 
centrifuged (100g, 10 min) to remove undissolved material. Collagen concentration was 
determined by freeze drying and weighing the residue of a known volume and adjusted 
to a concentration of 1.55mg/ml in 0.1% acetic acid. Neutralized collagen was made by 
adding 1.7 volumes of collagen to 0.4 volumes of a 2:1 mixture of 10-fold concentrated 
DMEM (Imperial Laboratories) and 0.34 M NaOH.        
  For culturing cells on top of collagen gels, 0.8 ml collagen was poured 
into each well of 12-well culture plates, and allowed to settle for 2 h at 37oC. The 
stromal cells and tumour cells suspended in DMEM with 10% FCS were plated on top 
of each collagen gel at an initial density of 1 x105 cells/ml for stromal cell and 5 x 104 
cells/ml for Caco-2 and HT-29 cells. Co-cultures were also done by plating a mixture of 
stromal cells  (1 x105 cells/ml) with Caco-2 or HT-29 cells (5 x 104 cells/ml) suspended 
in DMEM with 10% FCS on top of collagen gels.
  For 3-dimensional cultures, cells were cultured within collagen gels. 
Cells dissolved in DMEM with 10 % FCS were added (1 x105 cells/ml for stromal cells 
and 5 x 104 cells/ml for Caco-2 and HT-29 cells) to neutralized collagen. For co-cultures 
mixtures of stromal cells (1 x105 cells/ml) and Caco-2 and HT-29 cells (5 x 104 cells/ml) 
were added to neutralized collagen. Two ml of cell-collagen suspension was pipetted 
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into each well of 12-well culture plates. Plates were brought to 37oC to obtain gelation. 
After gelation, DMEM with 10% FCS was added on top of the gel. After growth for 48 
hours the wells were subjected to different experimental conditions. For single cultures 
of Caco-2 cells and HT-29, and co-cultures, the cells were grown in DMEM with 10% 
FCS or 1% FCS for 14 days, and the media were replaced every 2-3 days. For single 
cultures of stromal cells, after 48 h growth in DMEM with 10% FCS, the media were 
replaced with DMEM with 1% FCS, supplemented with growth factors to be tested, or 
Caco-2 or HT-29 conditioned media. The following growth factors were used: TGF-β 
(3 ng/ml), PDGF (50 ng/ml), EGF (10 ng/ml), IGF-I (10 ng/ml) and IGF-II (50 ng/ml). 
The cells were grown for 14 days, changing the experimental media every 2-3 days, and 
the gels were fixed in 4% buffered formaldehyde for 24 h. 
Immunocytochemistry and immunohistochemistry
Immunolabelling of ECM components tenascin-C, chondroitin sulphate (CS), 
chondoitin-6-sulphate (C-6-S) and versican, vimentin, desmin and α-smooth muscle 
actin was performed on cells grown on glass slides and on serial sections cut from 
collagen gels. The fixed cells on microscopic slides were washed three times with PBS 
containing 0.05% Tween 20. Serial sections from paraffin embedded gels were cut and 
de-waxed. For labelling of antigens with antiversican (2B1), deparaffinized sections 
were pre-treated with chondroitinase 0.2 U/ml ABC (Seikagaku, Kogyo, Tokyo, 
Japan) in 0.2 M Tris-HCL buffer (pH 8.0) at 37oC for 1 h. For tenascin-C labelling, 
deparaffinized sections were pre-treated with trypsin 0.1% in PBS (0.01M, pH 7.4) 
containing CaCl
2 
0.1% at 37oC for 10 min. Slides and sections were blocked with 1:20 
normal horse serum for 20 min. Primary antibodies, their sources, and dilutions used 
are shown in Table 1. Antibodies and blocking solutions were prepared in 1% bovine 
serum albumin/PBS. Primary antibody incubations were carried out for 18 h at 4oC, 
and secondary antibody incubations were carried out for 30 min at room temperature. 
Fig 1. Morphology
a) Caco-2 and stromal cell co-culture on monolayers; 
cells segregated after 48 h into distinct populations 
with stromal cells surrounding nests of Caco-2 cells. 
Haematoxylin. x 200
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After incubation with horse anti-mouse biotin and avidin-biotin peroxidase complex 
(Vector, Burlingame, USA), the colour was developed in 3-3’-diaminobenzidine and 
0.02% H
2
O
2
 in Tris buffer pH 7.8. The sections were counter-stained with 10% Mayer’s 
haematoxylin. The intensity of extracellular matrix protein expression was evaluated for 
immunohistochemical reactivity by semi-quantitative scoring in 4 grades (+++, intense; 
++, moderate; +, weak and -, negative). Myofibroblasts transformation was evaluated as 
the percentage of stromal cells positive for α-SMA. 
Results
1. Morphology. 
 When grown in monolayers, canine primary stromal cells presented 
themselves as large mesenchymal cells with many cytoplasmic extensions. When 
grown in monolayers with DMEM containing 10% FCS, all the cells were positive 
for vimentin and negative for desmin, and ~20% were positive for α-SMA, showing 
that FCS contains a factor which induces myofibroblast transformation. The number of 
Figure 2. Tenascin-C expression
a) Caco-2 cells on monolayers; no tenascin-C immune 
reactivity. Avidin-biotin peroxidase complex (ABC), 
haematoxylin counter-stain. 
b) Stromal cells on monolayers; weak tenascin-C 
immune reactivity. ABC, haematoxylin counter-stain. 
x 200 (refer to colour picture page 157)
c) Caco-2 and stromal cell co-culture monolayers; 
strong tenascin-C immune reactivity in stromal cells 
and moderate immune reactivity in Caco-2 cells. ABC, 
haematoxylin counter-stain. x 200
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d) Caco-2 cells on monolayers- addition of 
tumour cell-conditioned media; moderate 
tenascin-C immune reactivity. ABC, 
haematoxylin counter-stain. x 200 (refer to 
colour picture page 157)
e) Caco-2 cells on monolayers- addition of 
TGF-β; strong tenascin-C immune reactivity. 
ABC, haematoxylin counter-stain. x 200 (refer 
to colour picture page 157)
α-SMA positive cells decreased to <5% when the cells were grown for 48 h in serum 
free medium. When stromal cells were co-cultured with Caco-2 and HT-29 cells on 
monolayers, the cells segregated after 48 h into distinct populations with stromal cells 
surrounding nests of Caco-2 cells or HT-29 cells (Fig. 1a), and all the stromal cells were 
positive for vimentin and negative for desmin, and 100% were positive for α-SMA.
  Stromal cells grown inside collagen gel proliferated fast, assuming a 
spindle shape, sending thin cytoplasmic processes into the collagen. After 14 days of 
culture with media containing 10% FCS, ~ 25% of the cells expressed α-SMA. The 
number of α-SMA expressing stromal cells decreased to <15% when grown in gels with 
medium containing 1% FCS. The behaviour of Caco-2 and HT-29 cells in collagen gels 
differed from behaviour in normal monolayer. In monolayers, cells displayed a typical, 
Figure 3. Versican expression
a) Caco-2 cells on monolayers; no versican immune reactivity. ABC, haematoxylin counter-stain. x 200
b) Stromal cells on monolayers; no versican immune reactivity. ABC, haematoxylin counter-stain. x 100
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cuboidal morphology. In collagen gels, they became rounded and remained quiescent, 
even at high concentration of 5 x 106 cells/ml. After 14 days, few cells proliferated 
forming solid aggregates, where the rest necrotized. When Caco-2 or HT-29 cells 
c) HT-29 and stromal cell coculture monolayers; strong 
expression of versican in and around stromal cells. 
ABC, haematoxylin counter-stain. x 200 (refer to 
colour picture page 157)
Table 3. Effect of co-culturing, tumour cell-conditioned media, and growth 
factors on myofibroblasts differentiation of stromal cells in collagen gels.
*Culture Conditions % of stromal cells positive for α-SMA
Monolayers                       Gels
10%FCS 20 25
NFCS or 1%FCS <5 <15
Co-culture with Caco-2 cells >70 100
Co-culture with HT-29 cells >70 100
Caco-2-CM 60 >90
HT-29-CM 60 >90
TGF-β >90 100
PDGF <5 <15
bEGF <5 <15
IGF-I <5 <15
IGF-II <5 <15
*FCS=fetal calf serum, NFCS=no fetal calf serum, S-CM=stromal cell-conditioned media, Caco-2-
CM=Caco-2 cell-conditioned media, HT-29-CM=HT-29-conditioned media. Each experimental condition 
was assayed in triplicate, and three independent experiments were performed and the mean values are 
shown above.
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Figure 4. α-SMA expression in stromal cells
a) Stromal cells cultured on monolayers with serum free media; ~20% of the cells are positive for α-SMA. 
ABC, haematoxylin counter-stain. x 200 (refer to colour picture page 157)
b) Co-culture of stromal cells with Caco-2 on monolayers; >70% of the cells expressing α-SMA. ABC, 
haematoxylin counter-stain. x 200 (refer to colour picture page 157)
c) Stromal cells cultured on monolayers with Caco-2 cell-conditioned media; ~60% of the cells expressing 
α-SMA. ABC, haematoxylin counter-stain. x 200
d) Stromal cells cultured on monolayers with TGF-β; >90% of the cells expressing α-SMA. ABC, 
haematoxylin counter-stain. x 200
were co-cultured with stromal cells, or stromal cell-conditioned media, there was no 
tumour cell necrosis, and both Caco-2 and HT-29 cells formed glandular structures with 
lumina.
  
2. Deposition of Extracellular Matrix Components (Table 2)
  In both monolayers and 3-dimensional cell cultures in gels, there 
was no tenascin-C immunoreactivity in Caco-2 cells (Fig. 2a), and there was a weak 
cytoplasmic reactivity in HT-29, and a weak cytoplasmic reactivity in stromal cells (Fig. 
2b). Co-culturing of Caco-2 or HT-29 and stromal cells resulted in a strong tenascin-
C immunoreactivity in the stromal cells and granular tenascin immunoreactivity the 
tumour cells (Fig. 2c). Culturing of stromal cells with Caco-2 or HT-29-conditioned 
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media resulted in an increase in tenascin-C immnoreactivity from weak to moderate 
in the stromal cells, and this response was partially blocked by a TGF-β-neutralizing 
antibody. Culturing Caco-2 or HT-29 cells with stromal cell-conditioned media induced 
a strong tenascin-C expression in Caco-2 cells (Fig. 2d) and increased tenascin-C 
expression from weak to strong in HT-29 cells, and this response was partially blocked 
by a TGF-β-neutralizing antibody.
  Addition of TGF-β to the media in both monolayers and 3-dimensional 
cell cultures resulted in a strong expression of tenascin-C in stromal cells. Addition of 
TGF-β also induced strong tenascin-C expression in Caco-2 cells (Fig. 2e) and increased 
tenascin-C expression from weak to strong in HT-29 cells. Addition of PDGF, bFGF, 
IGF-I, and IGF-II did not affect tenascin-C expression in Caco-2 and HT-29 cells.  
Chondroitin sulphate, chondoitin-6-sulphate and versican (Table 2)
  In monolayers there was no immunoreactivity of CS, C-6-S and 
versican in Caco-2 and HT-29 cells (Fig. 3a). There was weak chondroitin sulphate 
immunoreactivity, and no versican (Fig. 3b) immunoreactivity in stromal cells. Co-
culturing of Caco-2 or HT-29 cells and stromal cells resulted in strong expression of 
versican in and around stromal cells (Fig. 3c). Culturing of stromal cells with Caco-2 or 
HT-29-conditioned media resulted in strong versican immunoreactivity in stromal cells. 
Addition of TGF-β or PDGF to the media resulted in a strong immunolabelling of CS, 
C-6-S and versican in stromal cells. Addition of stromal cell conditioned media or TGF-
β, PDGF, bFGF, or IGF-II to tumour cells did not induce versican expression in Caco-2 
or HT-29 cells.
  In 3-dimensional cultures, the results were similar as in monolayers, 
except that TGF-β and tumour cell conditioned media induced a moderate intensity 
rather than a strong intensity of versican expression in stromal cells. 
3. Myofibroblast differentiation (Table 3)
  In monolayers, immunolabelling of stromal cells grown in media 
with 10% FCS for 48 h showed that ~20% of the stromal cells were positive for α-
SMA (Fig. 4a).  Growing the stromal cells in serum free media for 48 h resulted in 
<5% of the cells expressing α-SMA. Co-culturing stromal cells with Caco-2 cells or 
HT-29 on monolayers or gels resulted in >70% of the cells expressing α-SMA (Fig. 
4b). The cytoskeleton in the stromal cell was much more brightly stained and many 
individual actin filaments were discernable. Culturing stromal cells with Caco-2 or HT-
29-conditioned media resulted in an increase in the number of stromal cells expressing 
α-SMA (~60%) (Fig. 4c). As expected, treating the stromal cells with TGF-β resulted 
in  >90% of the cells expressing α-SMA (Fig.4d). Addition of PDGF, EGF, IGF-I and 
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IGF-II did not affect α-SMA expression.   
  In 3-dimensional cell cultures, growing stromal cells in media with 
10% FCS for 14 days resulted in ~20% of the cells expressing α-SMA, and culturing of 
the stromal cells in media containing 1% FCS resulted in a decrease in the number of 
cells  (<5%) expressing α-SMA. Co-culturing, growth in Caco-2 or HT-29-conditioned 
media and addition of growth factors resulted in similar results as those obtained in 
growing on monolayers, except that addition of PDGF in gels resulted in a decrease 
(<5%) in the number of cells expressing α-SMA. 
Discussion
Signals transmitted from stromal cells to tumour cells or vice versa can occur through 
direct cell-cell contact, in the form of growth factors or through secretion of ECM 
proteins, and this constitutes the basis of reciprocal mesenchymal-epithelial interaction. 
In this study, we used two models (monolayer and 3-dimensional cell-to-cell interaction 
model) of stromal–tumour cell co-culture systems to investigate the regulation of ECM 
components production and cell differentination.
  Our study using a 3-dimensional co-culture system revealed that 
stromal cells reduce tumour cell necrosis, and promote cell differentiation (formation of 
glandular structures). Previous experiments of others (Olumi et al., 1998) have shown 
that death of cultured LNCaP tumour cells is 5-fold less when they are co-cultured with 
normal human prostatic fibroblasts in comparison to when cultured alone. Proliferation 
of the tumor cells was similar when co-cultured with normal human prostatic fibroblasts 
or when grown alone. These data suggest that stromal cells promote tumour progression 
through attenuation of cell death rather than increased proliferation. The ability of 
normal fibroblasts to induce differentiation of tumour cell lines such as of a human 
colon carcinoma cell line (Halttunen et al., 1996), or a human breast cell line (Shekhar et 
al., 2001), has been demonstrated in our study as well. Furthermore, our results showed 
that this stromal-induced differentiation is not mediated by the growth factors (TGF-β, 
PDGF, EGF, IGF-I and IGF-II) tested. Hepatocyte growth factor/scatter factor (HGF/
SF) has been shown to induce colon carcinoma cell line differentiation, (Brinkmann et 
al., 1995), and this unfortunately could not be tested in our study.        
   In previous studies where HT-29 cells were grown in a 3-dimensional 
culture system with human embryonic lung fibroblasts or skin fibroblasts (Halttunen 
et al., 1996), the HT-29 failed to form glandular structures. This is in contrast to the 
present study, where canine mammary stromal cells induced HT-29 cell differentiation. 
This observed difference may result from variations in the establishment of reciprocal 
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interactions between epithelial cells and mesenchymal cells, which can affect signal 
transmission, and this suggests that the origin of stromal cells is important for epithelial 
cell differentiation as shown by Shekhar et al. (2001).
  Of interest in our investigation was the regulation of the synthesis of the 
ECM proteins: tenascin-C, CS-PGs and versican, because these proteins are expressed 
in large quantities in a variety of human malignant tumours (Koukoulis et al., 1991; 
Hauptmann et al., 1995; Ricciardelli et al., 1997; Ricciardelli et al., 1998; Karvinen et 
al., 2003). In this experiment both epithelial cells and stromal cells were able to produce 
tenascin-C. This agrees with previous experiments (Ishihara et al., 1995; Vollmer et al., 
1997). In vivo, the quantitative and qualitative contribution to tenascin-C accumulation 
by epithelial tumour cells and stromal cells remains to be investigated. Identifying the 
cellular source of tenascin-C may be important since epithelial cells and stromal cells 
might secrete different tenascin-C isoforms with different functions. In this study, 
stromal cells were able to induce tenascin-C secretion by tumour cells and vice versa, 
suggesting that paracrine interaction between tumour and stromal cell is important for 
tenascin-C synthesis. To investigate factors responsible for the increased tenascin-C 
expression, we cultured stromal cells in Caco-2 or HT-29 conditioned media, and 
we also cultured tumour cells in stromal cell-conditioned media and obtained almost 
the same results as with co-cultures. This suggests that modulation of stromal cells 
by tumour cells and vice versa to secrete tenascin-C was due to some soluble factors 
in the conditioned media. Culturing of stromal or tumour cells with various growth 
factors (PDGF, EGF, IGF-I and IGF-II) showed that only TGF-β was responsible for 
the increase and induction of tenascin-C secretion. This is in accordance with previous 
reports (Vollmer et al., 1997; Wilson et al., 1999; Tuxhorn et al., 2002).
  Other ECM matrix components that have a prognostic value in cancer 
include CS-PGs (Ricciardelli et al., 1997) and versican (Ricciardelli et al., 1998, 2002). 
In our study, co-culturing of stromal cells and tumour cells increased the production 
of CS, C-6-S and versican. Their increased production was mediated by PDGF and to 
a lesser extent by TGF-β (Haase et al., 1998; Evanko et al., 2001). PDGF and TGF-β 
have been shown to increase the net synthesis of versican by stimulating transcription, 
translation and increase the glycosaminoglycan chain length (Schonherr et al., 1991).
  In vivo, myofibroblasts are the main stromal cells in colorectal tumour 
(Sappino et al., 1989; Mukaratirwa et al., 2003), and are responsible for the synthesis of 
ECM proteins (Powell et al., 1999). We, therefore, investigated whether co-culturing of 
stromal cells and tumour cells has an effect on the phenotypic transformation of stromal 
cells to myofibroblasts, and whether the same mediators that are responsible for ECM 
synthesis, also induce myofibroblast differentiation. We showed co-culturing of stromal 
cells with tumour cells resulted in transformation of stromal cells to myofibroblasts, 
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and that TGF-β enhanced and PDGF reduced stromal transformation to myofibroblasts. 
Similar results have been observed in a variety of stromal cells from rats (Desmouléire 
et al., 1993; Lijnen et al., 2003), rabbits (Nakamura et al., 2002) and humans (Peehl and 
Sellers, 1998; Valenti et al., 2001, Kinner et al., 2002). Myofibroblasts may stimulate 
tumour progression by stimulating the growth of a cancer cell population (Atula et al., 
1997; Nakamura et al., 1997), sustaining blood vessel formation and lymphangiogenesis 
(Orimo et al., 2001), attenuating cancer cell death (Olumi et al., 1998), and stimulating 
invasion and metastasis by activating proteolysis (Basset et al., 1990; Singer et al., 
1997).
  Combining our results on phenotypic modulation of stromal cells by 
tumour cells and the modulation of ECM components secretion, we conclude that TGF-
β is part of a paracrine system regulating stromal-epithelial cell interaction. The first 
step in this pathway might be induction of myofibroblast differentiation of stromal cells. 
The second step might be the induction of myofibroblasts to secrete ECM proteins, 
which in turn regulate tumour cell differentiation, proliferation and invasion. 
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General Summarizing Discussion 
  For many years, the stroma and extracellular matrix of tumours have 
been considered as only supportive. However, it is becoming more and more apparent 
that throughout the process of tumourigenesis (initiation, promotion, and progression), 
stromal cells and ECM components of the local host tissue can be active participants. 
Studies reported on this thesis focused on the role of stromal cells and ECM molecules 
in the progression and promotion of canine gastrointestinal (GIT) tumours and canine 
transmissible venereal tumours (CTVT). The phenotype of stromal cells and altered 
expression of ECM molecules, their temporal and spatial expression and possible role 
in the promotion and progression of canine GIT tumours and CTVT, was investigated in 
using immunohistochemistry (Chapter 3, 4, 5, and 7). The mechanisms of how tumour 
cells modulate the microenvironment were investigated by in vitro means by co-
culturing tumour and stromal cells (Chapter 8). The was done by studying the paracrine 
interaction tumour and stromal cells, with emphasis on how cytokines produced by 
tumour cells modulate phenotypic transformation of fibroblasts to myofibroblasts and 
the effect of these cytokines on the production of ECM molecules.  
 The major finding of this thesis is that there is phenotypic modulation of 
stromal cells by tumour cells, and there is altered expression of ECM proteins in canine 
GIT epithelial tumours and CTVT. In the first part of the thesis, we investigated using 
immunohistochemistry the phenotype and origin of stromal cells in GIT epithelial 
tumours, and the ECM molecules in these tumours. We demonstrated that the 
myofibroblasts is the most common stromal cell in GIT epithelial tumours, and most 
likely originated from pre-existing fibroblasts (Chapter 3), suggesting that these cells 
are important in tissue reorganisation and remodelling. We also found that that there is 
increased expression of the ECM molecules- tenascin-C, chondroitin sulphate, versican 
and hyaluronan. Although we failed to demonstrate that these ECM molecules could be 
used as independend markers of malignancy, the altered expression in tumours compared 
to normal tissue suggest that they play an important role in tumour progression.  
  In the second part of the thesis, we investigated using 
immunohistochemistry the temporal and spatial presence of stromal cells and expression 
of ECM molecules in CTVT. We found that there is extensive remodelling of the tumour 
stroma from progression to regression of CTVT, demonstrated by the temporal and 
spatial changes in the phenotype of stromal cells and the expression of ECM. From 
progression to regression, there was an increase in the number of myofibroblasts and 
an increase in tenascin-C expression, a situation resembling wound healing. During 
the progression phase there was high expression of hyaluronan, suggesting that 
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hyaluronan plays an important role in tumour progression.   
After concluding from immunohistochemistry experiments that there is phenotypic 
modulation of host stromal cells and altered ECM molecules in canine GIT tumours 
and CTVT, the intriguing question was the mechanisms involved in these processes. We 
addressed this question by in vitro studies involving tumour and stromal cell co-culture. 
We showed that there is paracrine interaction between tumour and stromal cells and this 
is responsible for the activation of stromal cells and changes in the proportions of ECM 
molecules favouring progression or regression of tumours.
  Combining the information in literature on the role of other stromal 
cells and ECM  (Liotta and Kohn, 2001; Tlsty and Hein, 2001), and our results on 
immunohistochemistry studies on tissues from canine GIT tumours and CTVT, and 
in vitro studies using tumour-stromal cell co-culture systems, we come up with a 
theoretical model (Fig. 1) on the modulation of the tumour microenvironment (stromal 
cells and ECM), and how the epigenetic changes influence tumour progression. In this 
model, the transformation or initiation of normal to neoplastic cell is preceded by, or 
concomitant with activation of local host stromal cells (Tomakidi et al., 1999).  In return, 
the activated stromal cells and altered ECM components influence tumorigenesis in the 
promotion and progression and regression phases by interference with the proliferation 
kinetics of the tumour cells. A variety of cell types populate the stromal compartment, 
ranging from immune, inflammatory cells, fibroblasts, myofibroblasts, and vascular cells 
(Rosenberg, 2001). The relative abundance of each cell type may change at the local site 
of tumour cell growth (Iozzo, 1988; Lee et al., 1999). For example, in GIT epithelial 
tumours there was activation of fibroblasts to myofibroblasts in tumours (Mukaratirwa 
et al., 2003), and in CTVT we found an increased number of T-lymphocytes during the 
regressing stages of the tumour. In addition to stromal cell activation, remodelling of 
the ECM, which is confined to the immediate pericellular environment of the tumour 
cells (Yoshida et al., 1997; Stamenkovic, 2003), seems to be a necessary step canine 
tumour progression. For example, in our experiments there was increased expression 
of tenascin-C, versican and hyaluronan in GIT epithelial tumours compared to normal 
tissue. From our in vitro studies and previous studies (Tuxhorn et al., 2002; Hauptmann 
et al., 2003), the transformation of fibroblasts to myofibroblasts, and the increased 
expression of tenascin-C and versican by myofibroblasts were mediated by cytokines 
(mainly TGF-β) secreted by tumour cells. The cytokines responsible for the phenotypic 
transformation of stromal cells and increased synthesis of ECM molecules could also be 
secreted by inflammatory cells (Kataki, et al., 2002).
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Fig. 1.Tumour microenvironment- activation stromal cells and altered ECM components expression. 
The first step is tumour initiation characterized by genomic alterations and present evidence shows that 
stromal cell and ECM components play no role in this process. Promotion of normal cell to tumour cell is 
preceded by the activation of host fibroblasts, immune cells and endothelial cells. Tumour cells produce 
cytokines such as TGF-β, which cause phenotypic transformation of fibroblasts to myofibroblasts, and also 
stimulates deposition of ECM. There is also autocrine effect of the cytokines produced by the tumour cells, 
inducing them to produce proteases, protease inhibitors and ECM molecules. Tumour cells also produce 
angiogenesis factors such VEGF and bEGF, which cause increased vascular permeability, endothelial cell 
proliferation, migration and invasion. Fibroblasts and myofibroblasts produce ECM molecules such as 
tenascin, versican and hyaluronan, which favours invasion, and also secrete chemoattractants such as SF/
HGF, which stimulates motility of tumour cells. Fibroblasts and myofibroblasts, and vascular endothelial 
cells secrete proteases and protease inhibitors, degrading the ECM, and clearing a pathway for the tumour 
cell. Immune cells might also modulate matrix directly by synthesizing proteases and protease inhibitors, 
or indirectly through activation of fibroblasts.
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Future prospects
  In view of future research, several areas need to be investigated and 
questions to be answered. First, is the phenotype of stromal cells, or the intensity of 
expression of tenascin-C, chondroitin sulphate, versican and hyaluronan related to 
survival rate or outcome in dogs with cancer?                                                             
  Second, can stroma cells develop oncogenic signals in the absence 
of a tumour? It is possible that stromal cells and their products (cytokines and ECM 
molecules) transform adjacent tissues in absence of pre-existing tumours by inciting 
phenotypic and genomic changes. In vitro experiments (Uchida et al., 1990; Atula et 
al., 1997; Barcellos-Hoff and Ravani, 2000) suggest that this mechanism of tumour 
generation is feasible.  However, the in vivo situation and the mechanisms involved 
need to be elucidated. Investigating the mechanism by which the oncogenic signals 
of the stroma facilitate the generation of malignant cells will provide insights into the 
generation of cancer cells.         
  Third, can stromal cells and ECM molecules expressed in tumours to 
be used as targets for therapy? Until recently, research on cancer therapy focused mainly 
on the cancer cells, and these cells are genotypically unstable and form a heterogenous 
population leading to drug resistance. Targeting elements of the microenviroment such 
as myofibroblasts and endothelial cell and onco-foetal ECM proteins (Liotta and Kohn, 
2001, 2002) which are genotypically stable, may inhibit tumour progression.
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Sunnary 
  In this thesis studies on temporal and spatial changes in stromal cells 
and extracellular matrix (ECM) molecules in canine gastrointestinal (GIT) tumours 
and canine transmissible venereal (CTVT) tumours are described. The mechanisms 
involved in the phenotypic transformation of fibroblasts to myofibroblasts, and ECM 
changes were investigated. The objectives of the investigations described in this thesis 
were: 
(1) to examine the phenotypes of stromal cells in canine tumours, 
(2) to examine the regulation and/or the expression of ECM components in canine 
tumours and 
(3) to elucidate the mechanisms involved in the modulation of stroma by tumour cells 
and vice-versa.                   
  The role of stroma and extracellular matrix proteins in tumourigenesis 
is briefly introduced in Chapter 1. Chapter 2 reviews the structure, localisation and 
function of tenascin-C and proteoglycans in normal tissues and it describes in vitro 
systems, and the role of tenascin-C and proteoglycans in canine tumourigenesis, and 
some of the mechanisms by which tumour cells modulate tenascin and proteoglycan 
expression. Generally, compared to man, dogs develop tumours twice as frequently, and 
most canine tumours progress at a more rapid rate than their counterparts in humans. 
Therefore to do separate research on canine tumours is needed. 
  In canine GIT epithelial tumours there is desmoplastic reaction. The 
origin and phenotype of the desmoplastic cells is not clear. In Chapter 3 a study on the 
type of stromal cells and tenascin-C expression in canine GIT tumours was presented. 
Using immunohistochemistry on fixed material, we found that the myofibroblast is the 
most common stromal cell in canine GIT epithelial tumours and most likely originated 
from pre-existing fibroblasts. Tenascin-C expression was absent in the normal mucosa 
of the stomach, but was expressed in the normal intestine with a gradual increase in 
intensity from the cryptal glands to the surface epithelium, suggesting tenascin-C was 
involved in shedding of enterocytes. Tenascin-C expression was increased in tumours 
compared to normal GIT mucosa. There was a strong co-localisation of tenascin-C and 
α-SMA expressing myofibroblasts, suggesting that myofibroblasts may be responsible 
for tenascin-C secretion, or the increase in number of myofibroblasts and tenascin-C 
expression may be the consequence of the same factor(s) produced by tumour cells. 
                                                                                                               
  Tenascin-C has been implicated in cell proliferation and adhesion 
by in vitro experiments. To find out whether this also occurs in vivo, in Chapter 4, 
the relationship between cell proliferation and tenascin-C expression in normal GIT 
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mucosa and tumours was outlined. There was no relation between cell proliferation and 
tenascin-C expression in both normal gut and tumour tissues studied. The absence of a 
correlation between tenascin-C and cell proliferation suggests that the main function of 
tenascin-C in both normal tissues and tumours of the canine GIT is anti-adhesion rather 
than proliferation. 
  Versican and hyaluronan are ECM components that are frequently 
increased in human tumours, and in vitro promote tumour progression through various 
mechanisms. In Chapter 5, we analysed the histological distribution of chondroitin 
sulphate, versican and hyaluronan in normal canine colonic wall and epithelial tumours. 
Versican expression was increased in the peritumoral stroma of carcinomas and reduced 
in adenomas, and in carcinomas a significant correlation was observed between versican 
intensity and grade of the tumour and versican intensity and depth of invasion. Unlike 
versican, hyaluronan expression was increased in the stromal tissue of both adenomas 
and carcinomas. However, there was no correlation between hyaluronan stromal 
intensity and grade of the tumour or depth of tumour invasion. These results suggest that 
altered levels of both versican and hyaluronan in canine colonic tumours affect tumour 
progression.         
 In Chapters 6 and 7, our investigations on the role of stroma and 
ECM were continued using canine transmissible tumour (CTVT), the only known 
naturally occurring tumour that can be transplanted as an allograft across major 
histocompatibility (MHC) barriers within the same species, and even to other members 
of the canine family. Chapter 6 reviews the cytogenetic origin, immunophenotype, 
and immunobiology of CTVT. This tumour represents a neoplastic microenvironment 
useful in the investigation of the role of stromal cells, ECM components and host 
immune response in tumour progression. In Chapter 7, we investigated the phenotype of 
stromal cells, and the expression of ECM proteins (tenascin-C, hyaluronan, chondroitin 
sulphate and versican) during the progression and regression stages of CTVT. 
  In CTVT, the number of stromal cell expressing α-smooth muscle actin 
(myofibroblasts) was significantly related to regressing tumours. These results suggest 
(that?) the modulation of stromal cells that occurs during the regressing stage in CTVT, is 
similar to that occurring during wound healing where pre-existing fibroblasts transform 
into myofibroblasts. Tenascin-C was weakly expressed in the stroma of tumours in the 
progressive stage and in regions of the regressing tumours with tumour infiltrating 
lymphocytes, but intensely expressed in the stroma of tumours in late regressive stage. 
In addition, tenascin-C was also expressed in the cytoplasm of some tumour cells in the 
late regressive stage. The intensity of the stromal tenascin-C signal was significantly 
associated with regressing tumours.  This temporal expression of tenascin-C is also 
similar to what happens during healing. The intensity of stromal hyaluronan signal and 
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the presence of tumour cell-associated hyaluronan  were both significantly associated 
with progressing tumours. This suggests hyaluronan is involved in the tumour growth. 
     The specific mechanisms of how tumour and 
stromal cells interact to modulate the microenviroment are not clear. In Chapter 8, we 
investigated the paracrine effects of tumour cells on stroma cells and vice versa on 
tumour cell morphology and differentiation, production of ECM components (tenascin-
C, chondroitin sulphate, chondroitin-6-sulphate, and versican), and phenotypic 
differentiation of stromal cells to myofibroblasts. We were able to show that canine 
stromal cells support tumour cell growth and differentiation. We also showed that 
tumour cells induce differentiation of stromal cells to myofibroblasts, and increased the 
synthesis of tenascin-C, chondroitin sulphate, and versican by stromal cells via TGF-β. 
These results suggest that TGF-β represents a paracrine system involved in stromal-
epithelial cell interaction important in stromal cell differentiation and ECM production 
in tumours.
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Samenvatting
In dit proefschrift worden studies beschreven naar veranderingen die zich voordoen in 
cellen in en de extracellulaire matrix (ECM) van het stroma van maagdarm tumoren 
en van zogenaamde CTV (canine transmissible venereal) tumoren van honden. Hierbij 
werd aandacht besteed aan de verdeling van de ECM in de tumoren en veranderingen 
in die verdeling in de loop van de tijd. Ook werden de mechanismen bestudeerd die 
betrokken zijn bij de fenotypische transformatie van fibroblasten in myofibroblasten en 
bij de verandering in de samenstelling van de ECM.
 De doelstellingen van het onderzoek van dit proefschrift waren
1. het vaststellen van het fenotype van de stromale cellen in de hondentumoren,
2. het bestuderen van de regulatie van de expressie van ECM componenten in 
hondentumoren en
3. het ophelderen van de mechanismen die betrokken zijn bij de omvorming van stroma 
door tumorcellen en omgekeerd.
 De rol van het stroma en de extracellulaire matrix in de ontwikkeling van 
tumoren wordt kort geintroduceerd in Hoofdstuk 1. Hoofdstuk 2 geeft een overzicht van 
de structuur, de lokalisatie en de functie van tenascine-C en proteoglycanen in normale 
weefsels en het beschrijft in vitro systemen; tevens beschrijft het de rol van tenascine-
C en proteoglycanen in de ontwikkeling van tumoren van honden en enige van de 
mechanismen waarmee tumorcellen de expressie van tenascine en proteoglycanen 
moduleren. Vergeleken met de mens ontwikkelen honden in het algemeen twee keer zo 
vaak een tumor en de meeste tumoren in honden groeien met een hogere snelheid dan 
dezelfde typen tumoren bij de mens. Daarom is apart onderzoek naar tumoren in honden 
noodzakelijk.
In maagdarm tumoren van honden komt vaak een desmoplastische reactie 
voor. De oorsprong en het fenotype van de desmoplastische cellen is niet duidelijk. 
In Hoofdstuk 3 wordt een onderzoek beschreven naar het type stromale cellen dat 
aanwezig is maagdarm tumoren van de hond en naar de expressie van tenascine-
C. Door het toepassen van immunohistochemie op gefixeerd materiaal konden we 
vaststellen dat myofibroblasten de meest algemene stromale cellen zijn  in de epitheliale 
maagdarm-tumoren van de hond en dat deze zeer waarschijnlijk afkomstig zijn van 
pre-existente fibroblasten. In de normale mucosa van de maag werd geen tenascine-
C expressie gevonden, maar in de normale darm kwam het tot expressie als een 
geleidelijke toename in intensiteit vanaf de klieren van de crypten tot aan het epitheel 
van het oppervlakte, wat suggereert dat tenascine–C betrokken zou kunnen zijn bij 
het afstoten van enterocyten. In vergelijking met de normale maagdarm mucosa was 
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tenascine-C verhoogd in tumoren. Er was een sterke co-localisatie van tenascin-C met 
myofibroblasten die werden herkend op grond van α-smooth muscle actine (α-SMA) 
expressie; dit suggereert dat myofibroblasten verantwoordelijk zijn voor tenascin-C 
secretie, of dat de toename in het aantal myofibroblasten en de tenascin-C expressie 
beide het resultaat zijn van dezelfde factor(en) geproduceerd door de tumorcellen.
 In in vitro experimenten is vastgeteld dat tenascine-C een rol speelt in proliferatie 
en hechting van cellen. Het is interessant om na te gaan of dit in vivo ook optreedt en 
daarom werd in Hoofdstuk 4 aandacht besteed aan de relatie tussen celproliferatie en 
tenascin-C expressie in de normale darm mucosa en in tumoren. Er was geen relatie te 
vinden tussen celproliferatie en tenascine-C expressie, noch in de normale darm noch 
in de tumoren. De afwezigheid van een dergelijke relatie tussen tenascine-C en cel 
proliferatie suggereert dat de belangrijkste functie van tenascine-C, zowel in normale 
weefsels als in de tumoren van het maagdarmkanaal bij de hond eerder te maken heeft 
met hechting en niet met proliferatie.
 Versican en hyaluronzuur zijn ECM componenten die in tumoren van de mens 
vaak zijn toegenomen in concentratie en in vitro bevorderen ze de groei en ontwikkeling 
van tumoren door middel van een verscheidenheid aan mechanismen. In Hoofdstuk 5 
werden de histologische verdeling van chondroitine sulfaat, versican en hyaluronzuur 
in de normale darmwand en epitheliale tumoren bestudeerd. De expressie van versican 
was verhoogd in het peritumorale stroma van carcinomen maar verlaagd in adenomen, 
en er werd een significante correlatie waargenomen tussen versican intensiteit en de 
gradatie van de tumor en de versican intensiteit en de diepte van invasie van de tumor. 
In tegenstelling tot versican was hyaluronzuur verhoogd in het stromale weefsel van 
zowel de adenomen als de carcinomen. Er was echter geen correlatie tussen de stromale 
hyaluronzuur intensiteit en de tumorgradering of de tumorinvasie. Deze resultaten 
suggereren dat veranderde niveau’s van zowel versican als hyaluronzuur invloed 
hebben op de tumorprogressie in colontumoren van de hond.
 In de Hoofdstukken 6 en 7  werden de studies naar de rol van stroma en ECM 
vervolgd door bestudering van CTV tumoren van de hond. Dit is de enige bekende 
natuurlijk voorkomende tumor die kan worden getransplanteerd als een allograft met 
voorbijgaan aan de major histocompatibility (MHC) grenzen  naar individuen van 
binnen eenzelfde soort, en zelfs naar individuen van andere leden van de hondenfamilie. 
Hoofdstuk 6 geeft een overzicht van de cytogenetische oorsprong, het immunophenotype 
en de immunobiologie van de CTV tumoren. De tumor kan worden beschouwd als 
een weefsel met een micro-omgeving die nuttig is voor het bestuderen van de rol van 
stromale cellen, ECM bestanddelen en de immuunresponse van de gastheer in de 
tumorprogressie. In Hoofdstuk 7 bestudeerden we het phenotype van de stromale cellen 
en de expressie van ECM eiwitten (tenascine-C, hyaluronzuur, chondroitine sulfaat en 
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versican) tijdens de progressie en de regressie fasen van de CTV tumor.
 In CTV tumoren was het aantal stromale cellen dat α-SMA tot expressie 
bracht (de myofibrobasten) significant gecorreleerd met het in regressie zijn van de de 
tumoren. Dit resultaat suggereert dat de verandering van stromale cellen die optreedt 
tijdens de regressiefase in CTV tumoren vergelijkbaar is aan het wondgenezingsproces 
waarbij pre-existente fibroblasten transformeren tot myofibroblasten. Tenascine-C 
kwam slechts zwak tot expressie in het stroma van de tumoren in de progressiefase 
en in de gebieden van de tumoren in regressie waarin lymfocyten infiltraties werden 
gevonden; het kwam sterk tot expressie in het stroma in de tumoren in de late fase 
van de regressie. Bovendien werd tenascine-C ook gevonden in het cytoplasma 
van sommige tumorcellen in de late regressiefase. De intensiteit van de stromale 
tenscine-C expressie was significant gecorreleerd met het in regressie zijn van 
tumoren. Deze tijdelijke expressie van tenascin-C is eveneens vergelijkbaar met wat 
gebeurt gedurende wondgenezing. De intensiteit van het stromale hyaluronzuur en 
de aanwezigheid van tumorcel-geassocieerd hyaluronzuur waren allebei significant 
geassocieerd met tumorprogressie. Dit suggereert dat hyaluronzuur betrokken is bij de 
groei van de tumor.
 De specifieke mechanismen van hoe tumorcel en stromale cel een interactie 
aangaan, waarmee ze de tumor micro-omgeving moduleren zijn niet duidelijk. In 
Hoofdstuk 8 werd het paracriene effect van tumorcellen op stromale cellen en omgekeerd 
bestudeerd met als meetgrootheden tumorcel morfologie en differentiatie, de productie 
van ECM bestanddelen (tenascine-C, chondroitine sulfaat, chondroitine-6-sulfaat en 
versican) en de phenotypische differentiatie van stromale cellen naar myofibroblasten. 
We konden aantonen dat stromale cellen van honden de groei en differentiatie van 
tumorcellen bevorderen. Ook kon worden aangetoond dat tumorcellen de differentiatie 
van stromale cellen tot myofibroblasten induceren en een verhoging teweegbrengen van 
de synthese van tenascine-C, chondroitine sulfaat en versican door de stromale cellen 
door middel van TGF-β. Deze resultaten suggereren dat TGF-β deel uitmaakt van een 
paracrien systeem dat betrokken is bij de interactie tussen stroma en epitheelcel, en 
daarin met name verantwoordelijk is voor de differentiatie van stromale cellen en de 
ECM productie in tumoren.
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